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ABSTRACT 
 
 Signals from adipose tissue, such as interleukin-6 (IL-6) and asymmetric dimethyl 
arginine  (ADMA),  an  endogenous  nitric  oxide  inhibitor,  explain  the  link  between 
obesity  and  metabolic  diseases.  Previously  published  human  studies  have  used 
omental  adipose  tissue  to  study  visceral  depots,  based  on  the  assumption  that  all 
visceral adipose tissues are similar. This study, for the first time, assessed the release 
of  five  adipokines  (adiponectin,  leptin,  IL-6,  MCP-1  and  RANTES)  from  the 
subcutaneous and two omental depots. Components of the cyclooxygenase (COX) 
and the nitric oxide (NO) pathways, that regulate cytokine release in other tissues, 
were also investigated for their putative role(s) in mediating adipokine release. 
RANTES release was greatest from the gastric fat pad. However, significantly higher 
circulating  RANTES  levels  suggest  that  adipose  tissue  is  unlikely  to  be  the  main 
source of RANTES release. 
Inhibition  of  the  COX  pathway,  especially  COX-2,  reduced  IL-6  release  from 
subcutaneous adipose tissue. Prostacyclin synthase (PGI2S) activity was higher in the 
omental tissue and its protein expression was elevated in the stromavascular fraction 
from this depot. PGI2S activity appears to mainly reside in the non-adipocyte cells 
and is more coupled to IL-6 production in adipose tissue.  
Serum insulin and CRP levels, and systolic blood pressure, directly associated with 
subcutaneous  tissue  ADMA  content,  while  BMI  correlated  with  omental  ADMA 
release. ADMA release was higher from the omental depot. However, while DDAH2 
expression was higher compared to DDAH1 in adipose tissue, there was no depot 
specific difference in the expression of either isoform.  
In  conclusion,  this  study  showed  adipose  depot  specific  differences  of  RANTES 
release, a novel adipokine, from a hitherto poorly studied depot, the gastric fat pad. 
Characteristics  of  the  omental  adipose  tissues  differed  depending  on  location  and 
paracrine factors that may mediate the adipokine release. These regulatory pathways 
included components of the COX and NO pathways. 
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1.1 OBESITY 
1.1.1 Epidemiology 
Obesity is the epidemic of the century and, contrary to some people’s belief, it is not 
simply  a  cosmetic  problem.  The  question  of  whether  obesity  should  be  called  a 
‘disease’ or, on the other hand, simply a ‘condition’ has gone on for more than 100 
years and has significant connotations for the approach one takes in its treatment, to 
the  regulation  of  medicines  used  for  its  treatment,  and  whether  health  care 
expenditures  associated  with  obesity  are  reimbursed  (Bray,  2004  (a)).  During  the 
early part of the 20th century the prevalence of obesity rose slowly, but around 1980 it 
began  to  rise  more  rapidly.  Children  are  affected  by  obesity,  with  the  prevalence 
rising from 5% in 1960 to 15% in 2000 (Ogden et al., 2000). Obesity is the most 
prevalent  nutritional  disorder  in  industrialised  countries  (Kushner,  2002). 
Approximately 60% of overweight 5 to 17 year old children already have associated 
biochemical or clinical cardiovascular risk factors, such as hyperlipidemia, elevated 
blood  pressure,  or  increased  insulin  levels,  and  25%  have  2  or  more  of  these 
(Freedman  et  al.,  1999).  It  is  associated  with  an  increased  risk  of  cardiovascular 
morbidity and mortality
 (Garrison et al., 1996), type 2 diabetes mellitus (Ogden et al., 
2000), osteoarthritis and cancer. In a published report (Drenick et al., 1980), mortality 
rates in patients who were
 morbidly obese is 12 times higher in men aged 25
 to 34 
years and 6 times higher in men aged 35 to 44 years compared to
 men with healthy 
weight of the same age. Obesity clearly increases health risk and the cost of health 
care (Klein et al., 2004 (a)) and despite all this evidence; many clinicians consider 
obesity to be a self-inflicted condition of little medical significance. The future of 
these adults and children is complications of heart disease, renal failure, blindness and 
amputation disabling them during the next 20 years or so.  
 
1.1.2 Causes of obesity  
Obesity is not a single disorder but a heterogeneous group of conditions with multiple 
causes. Body weight is determined by an interaction between genetic, environmental 
and psychosocial factors acting through the physiological mediators of energy intake 
and expenditure (Kopelman, 2000). 
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1.1.2.1 Energy imbalance 
An energy imbalance results in obesity. This state of imbalance can be described by 
the first law of thermodynamics, which says that the energy of a system is determined 
by the difference between the heat that enters that system and the heat that leaves. In 
the  case  of  obesity,  heat  is  from  food  energy,  and  the  quantity  of  energy  that  is 
expended  as  chemical  and  physical  energy  comes  from  metabolism  and  work.  In 
humans the unmetabolized foods are converted to fat and lead to obesity (Bray, 2004 
(a)).  The  most  variable  component  of  energy  expenditure  is  physical  activity. 
Epidemiological data show that low levels of physical activity and watching more 
television predict higher body weight (Hancox et al., 2004). The defects in metabolic 
mechanisms  that  control  energy  expenditure  have  not  been  described  in  human 
obesity (Kopelman, 2000).  
 
1.1.2.2 Genetics 
Obesity might run in the families but the influence of the genotype on the etiology of 
obesity may be attenuated or exacerbated by non-genetic factors (Kopelman, 2000). 
Genetic factors can be divided into two groups, the rare genes that produce significant 
obesity and a group of more common genes that underlie susceptibility to obesity, the 
so-called “susceptibility” genes (Rankinen et al., 2002). Single gene mutations, such 
as seen in humans with leptin and leptin receptor gene mutations, are rare and only 
constitute a minority of normal obesity (Zhang et al., 1994). Importantly, genetics 
related to obesity are not responsible for the epidemics of obesity in recent times as 
the gene pool in communities has not changed significantly (Koplan & Dietz, 1999). 
 
1.1.2.3 Environment 
Environment plays an important role in the etiology of obesity. Availability of food, 
fast  food  or  food  with  higher  energy  content,  socializing  with  food  and  drink, 
increased numbers and marketing of snack foods, and, on the other hand, decreased 
energy expenditure, perhaps due to decrease in children’s activity from watching TV, 
playing computer games or increasingly automated work places, are a few examples 
(Koplan  &  Dietz,  1999).  Environmental  factors  have  been  shown  to  affect  leptin 
sensitivity, as a high-fat diet leads to leptin resistance, although the basis for this is 
poorly understood (Friedman & Halaas, 1998).   15 
 
1.1.2.4 Other causes  
In most traditional societies, fatness has frequently been a symbol of motherhood in 
adult  women  (Brown  &  Bentley-Condit,  1998).  In  contrast,  the  cultural  ideal  of 
thinness is found in relatively few developed societies where motherhood is not the 
primary  means  of  female  status  attainment  (Anderson  et  al.,  1992).  There  is  also 
evidence to suggest that under nutrition of the foetus during intrauterine development 
may  determine  the  later  onset  of  obesity,  hypertension  and  type  2  diabetes 
independent of genetic inheritance (Barker, 1995). Viruses may also be a cause of 
obesity (Bray, 2004 (b)). The injection of several viruses into the central nervous 
system produces obesity in mice (Bray, 2004 (b)). A recent finding of antibodies to 
one  of  the  adenoviruses  at  significant  titres  in  obese  human  beings  raises  the 
possibility  that  viruses  are  involved  in  some  cases  (Dhurandhar  et  al.,  2000).  In 
experimental  animals,  exposure  in  the  neonatal  period  to  toxins  like  monosodium 
glutamate, a common flavoring ingredient in food, also produces obesity. A similar 
effect of reduction in glucose can also produce obesity, suggesting that the brain of 
growing animals, and possibly those of human beings, may respond with damage to 
the metabolic sensors that regulate food needs (Bray & Champagne, 2005). 
 
1.1.3 Indices and diagnosis of obesity 
Body  Mass  Index (BMI): This is an index of obesity and acts as an indicator of 
heaviness and only indirectly of body fat (Garn et al., 1986; Bouchard, 1992). It does 
not distinguish fat mass from fat free mass. Despite its limitations BMI is widely used 
clinically bacause of its simplicity to measure, low cost and reasonable correlation 
with body composition.  
Waist Hip Ratio (WHR): The correlation between WHR and abdominal visceral fat 
is positive but the association is characterized by a wide scatter of score (Bouchard & 
Perusse, 1998) and it does not provide a precise estimate of abdominal visceral fat.  
Skin fold thickness: This method is easy to use and it provides a precise assessment 
if performed at different sites and by the same person, but, the technique falls short in 
estimating the abdominal and intramuscular fat.   16 
Bioimpedence: The principle of this technique is that lean mass conducts current 
better than fat mass because it is primarily an electrolyte solution. A weak current 
(impedence) is applied across extremities and the resistance is measured which in turn 
estimates the body fat. It is easy and practical to use. However it is no more accurate 
than anthropometric measurements (Kopelman, 2000) and results largely depend on 
the hydration status of the patient. 
1.1.4 Types of obesity 
The perception that not all obese individuals are alike and that it would be useful to 
distinguish several types of obesity is an ancient one (Bray, 1990). Initially it was 
observed that male pattern of fat distribution, android obesity, carried a greater health 
risk than the female profile (Vague, 1956). However it was not until 1980s that it was 
shown with human and animal studies that android obesity  was a  greater risk for 
cardiovascular disease and type 2 diabetes mellitus (Bjorntorp, 1985; Kissebah et al., 
1982).  The  Nurse  Health  Study  found  that  the  risk  of  type  2  diabetes  mellitus 
increases  with  the  degree  and  duration  of  overweight  and  with  a  more  central 
distribution of body fat (Colditz et al., 1995).  
 
1.1.5 Consequences of obesity  
Negative effects of excess weight on morbidity and mortality have been recognized 
for more than 2000 years. Hippocrates stated that “sudden death is more common in 
those who are naturally fat than in the lean”. The pathophysiological effects of obesity 
may now be attributed to two factors: first, the increased mass of adipose tissue and, 
second, the secretion of pathogenic products from the enlarged fat and non-fat cells 
from these tissues. Sleep apnea, secondary to increase in para-pharyngeal fat deposits, 
osteoarthritis  and  social  stigma  are  examples  of  the  first  category.  The  second 
category includes the metabolic effects brought on by distant effect of factors secreted 
from  adipose  tissue  (Bray,  2004  (c))  namely  type  2  diabetes  mellitus,  insulin 
resistance and the metabolic syndrome, hypertension, cardiovascular disease, some 
cancers, as well as, non alcoholic fatty liver and gallbladder disease. 
 
1.1.5.1 Type 2 diabetes mellitus, insulin resistance and the metabolic syndrome 
Weight gain appears to precede the onset of diabetes and increases its risk. Weight 
loss or moderate weight gain over years reduces the risk of developing type 2 diabetes.   17 
The Swedish Obese Subject study reported 13 –16% of obese subjects presenting with 
diabetes at baseline (Sjostrom et al., 1997) and in the Nurses Cohort Study, BMI was 
the dominant predictor of the risk of type 2 diabetes after adjustment for age (Colditz 
et al., 1995). It is not surprising therefore that the worldwide epidemic of obesity has 
been accompanied by a surge in the incidence of type 2 diabetes (Engelgau et al., 
2004). Normally, control of blood glucose levels depends on the efficient action of 
insulin, which stimulates uptake of glucose from the blood into muscle and fat cells 
through  GLUT4,  an  insulin-regulated  glucose  transporter.  It  also  inhibits  glucose 
production in liver, thereby maintaining normal glucose levels in the blood. In adipose 
tissue, glucose provides fuel for the synthesis of fat stores, which serve as the body’s 
main energy reservoir (Muoio & Newgard, 2005). The insulin mechanism of glucose 
control fails in both obesity and type 2 diabetes. The onset of this ‘insulin-resistant’ 
condition is closely associated with weight gain (Engelgau et al., 2004), suggesting 
that  increased  adipose  tissue  generates  signals  that  interferes  with  the  action  of 
insulin.  On  the  other  hand  the  expression  of  GLUT4  is  greatly  reduced  in  the 
adipocytes but not in the muscle cells of rodents and humans that are obese and have 
insulin  resistance  (Kahn,  1994).  The  changes  in  the  body’s  insulin  action  occur 
through  alterations  in  the  sensitivity  of  muscle  and  liver  cells  to  insulin.  This 
implicates  the  presence  of  an  adipose  secreted  substance  that  allows  fat  to 
communicate  with  peripheral  tissues.  However  the  responsible  adipose-derived 
factor(s) has not been found (Muoio & Newgard, 2005). Recently a factor derived 
from  fat  cells,  called  retinol  binding  protein-4  (RBP4)  has  been  shown  to  impair 
insulin  sensitivity  throughout  the  body.  RBP4  joins  a  growing  list  of  fat-derived 
peptides that modulate glucose homeostasis (Yang et al., 2005). Insulin insensitivity 
leads to compensatory hyperinsulinaemia which in turn, increases hepatic VLDL and 
triglyceride  synthesis  and  secretion  (Bray,  2004  (c)).  It  therefore  has  significant 
correlation  with  a  dyslipoproteinaemic  state  (Sniderman  &  Cianflone,  1995). 
Expectantly, insulin resistance is the hallmark of the metabolic syndrome, which has 
been defined by the National Cholesterol Education Program Adult Treatment Panel 
III as having any three of the following five criteria: abdominal obesity, low HDL, 
high triglycerides, high fasting glucose and hypertension.  
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1.1.5.2 Cardiovascular disease and hypertension 
Blood pressure often is increased in overweight individuals (Rocchini, 1998). In the 
Swedish Obese Subject Study, hypertension was present at baseline in 44-51% of the 
obese subjects. Also the Nurses Cohort Study found the risk of cardiovascular disease 
increased twofold in women with a BMI between 25 and 28.9, and 3.6-fold for a BMI 
>29, compared with women with a BMI of less than 21 (Willett et al., 1995). On the 
other hand the association between obesity and the risk of death from cardiovascular 
disease was confirmed by a study of 8373 Finnish women (aged 30–59 yr) followed 
for 15 yr in the Finnish Heart Study. This study found that for each increase in body 
weight of approximately 1 kg, the risk of coronary mortality increased by 1–1.5% 
(Jousilahti et al., 1996). Obesity is associated with an increase in total blood volume 
and  cardiac  output  and  a  decrease  in  peripheral  vascular  resistance  (Alpert  et  al., 
2001).  The  total  blood  volume  is  increased  in  proportion  to  body  weight.  This 
increase in blood volume contributes to an increase in the left ventricular preload and 
an increase in resting cardiac output (De Divitiis et al., 1981). The increased demand 
for cardiac output is achieved by an increase in stroke volume while the heart rate 
remains  comparatively  unchanged.  The  obesity-related  increase  in  stroke  volume 
results from an increase in diastolic filling of the left ventricle (Licata et al., 1991) 
and the left ventricular dilatation is accompanied by myocardial hypertrophy which 
over  time  can  progress  to  heart  failure  (Kopelman,  2000).  Left  ventricular  mass 
increases directly in proportion to BMI or the degree of overweight (Lauer et al., 
1991) and the severity of the defects in cardiac structure and function is associated 
with  both  the  degree  and  duration  of  obesity  (Alpert  et  al.,  1995).  Weight  loss, 
particularly in persons  who are severely obese, can improve cardiac structure and 
function (Alaud-din et al., 1990).  
 
1.1.5.3 Other organs 
An increased amount of fat in the chest wall and abdomen results in reduction in lung 
volume and decrease in its compliance. These changes are significantly exaggerated 
when an obese person lies flat. In some cases obstruction occurs in the larynx and is 
associated with loss of tone of the muscles controlling tongue movement (Kopelman, 
2000). This leads to sleep apnea where sleep is disturbed with frequent awakening 
because of apnoeic episodes. The persistent hypoxia/hypercapnia, leads to pulmonary   19 
hypertension secondary to the superimposed increased circulatory volume which in 
turn develops right sided cardiac failure. It can also lead to myocardial perfusion 
defects (Orea-Tejeda et al., 2003). There is a consensus that obesity is associated with 
an increased risk of cancer of the breast and endometrium in postmenopausal women, 
kidney, colon (strongest in men) and oesophagus (Calle & Thun, 2004). However, 
studies examining the influence of obesity and overweight on other malignancies i.e. 
prostate, liver, stomach, bladder, lymphoma and leukaemia, reveal inconclusive 
findings (Bianchini et al., 2002). Although the reasons are not clear the increased risk 
of endometrial and breast cancer in overweight women may be because of the 
increased production of oestrogens by adipose tissue (Schapira et al., 1994). 
Cholelithiasis is the primary hepatobiliary pathology associated with overweight (Ko 
& Lee, 2004). This is thought to be due to increased cholesterol turnover related to 
total body fat (Bray, 2003) which is in turn excreted in the bile. Non alcoholic fatty 
liver disease is also seen in obese individuals. This is a collection of liver 
abnormalities, including hepatomegaly, elevated liver enzymes, liver steatosis, 
steatohepatitis, fibrosis, and cirrhosis (Matteoni et al., 1999).  
 
1.1.6 Treatments 
Treatment of obesity is generally divided into medical and surgical options. Medical 
treatment  usually  consists  of  dietary  and/or  drug  therapy  in  combination  with 
behavior  modification  and  exercise,  while  surgery  is  reserved  for  patients  with 
clinically severe or morbidly obesity.  
 
1.1.6.1 Behaviour and lifestyle 
Behavioral treatments help obese individuals to develop adaptive thinking, eating, and 
exercise habits that enable them to decrease their weight and avoid regaining weight. 
People who combine caloric restriction and exercise with behavioral treatment may 
expect to lose about 5 to 10% of their body weight over a period of four to six months. 
Patients however are generally unwilling to continue behavioral treatment indefinitely 
(Wadden & Foster, 2000). 
 
1.1.6.2 Diet 
As energy imbalance is one of the main causes of obesity, the solution for obesity 
should be as simple as eating less and exercising more. Studies have shown that the   20 
better the adherence to a diet, the greater the weight loss (Lyon et al., 1995). Thus, it 
is adherence to diets, not diets themselves, that makes the difference (Dansinger et al., 
2005). Although simple in theory, applying the ideas of energy balance and counting 
kilocalories to body weight control has proven unsuccessful.  
 
1.1.6.3 Exercise 
Exercise is commonly promoted as an important component of a weight loss regimen. 
However studies have shown that moderate exercise, per se, is ineffective as a means 
of achieving weight loss (Meredith et al., 1989). Exercise however is an excellent way 
to promote preservation of lean body mass during dieting. It also appears to be more 
important in maintaining weight loss than in achieving it (Pavlou et al., 1989). 
 
1.1.6.4 Pharmacotherapy 
There are five modes of action for drug therapy of obesity; 1) reducing food intake. 2) 
blocking fat absorption 3) increasing thermogenesis by uncoupling of fuel metabolism 
from the generation of ATP, thereby dissipating food energy as heat 4) regulating fat 
synthesis/lipolysis  or  adipose  differentiation/apoptosis  5)  modulating  the  central 
controller regulating body weight (Bray and Tartaglia, 2000). The two drugs currently 
available  licensed  for  use  in  the  United  Kingdom  are  Sibutramine  and  Orlistat. 
Sibutramine  is  a  β-phenethylamine  that  selectively  inhibits  the  re-uptake  of 
noradrenaline, serotonin and, to a lesser extent, dopamine and thus results in reduction 
of food intake. Studies have shown a dose-related reduction in body weight (Bray et 
al., 1999), with weight loss of up to 9% below baseline, which can last up to 18 
months with continued treatment. Orlistat is a hydrogenated derivative of a bacterial 
lipase inhibitor that blocks pancreatic lipase, thus decreasing triglyceride digestion 
(Guercolini, 1997). Two published clinical trials, each lasting two years, have shown 
that after one year the drug produces a weight loss of about 9–10% compared with a 
4–6% weight loss in a placebo-treated group (Sjostrom et al., 1998; Davidson et al., 
1999). Drugs have a useful place as part of the treatment for some overweight patients. 
However studies indicate that regaining of weight is extremely likely when weight-
loss  medications  are  discontinued  (National  Task  Force  on  the  Prevention  and 
Treatment  of  Obesity,  1993).  The  safety  and  efficacy  of  weight  loss  medications 
beyond two years of use have not been established (Yanovski & Yanovski, 2002) and 
therefore their long-term use must be risk assessed.    21 
 
Metformin 
Metformin is an insulin-sensitizing and antihyperglycemic agent used in the treatment 
of type 2 diabetes mellitus. The exact mechanism of action of Metformin is unknown, 
but  one  of  its  suggested  actions  is  increased  peripheral  glucose  disposal  at  lower 
insulin concentrations (Nosadini et al., 1987; Prager et al., 1988; Groop et al., 1989).  
It has been shown that Metformin treatment of obese adults with NIDDM results in 
weight loss and improved glucose tolerance and lipid profiles (Hermann et al., 1992; 
Bailey, 1992; Abbasi et al., 1998). Furthermore, the use of Metformin in non-diabetic 
obese adults has been demonstrated to cause reduced food intake and weight loss with 
reduction  in  fasting  plasma  glucose,  cholesterol,  and  insulin  concentrations 
(Fontbonne et al., 1996; Lee et al., 1998). On the other hand, short-term Metformin 
treatment in women with polycystic ovary syndrome and insulin resistance has been 
shown  to  improve  insulin  sensitivity  without  a  significant  effect  on  body  weight 
(Diamanti-Kandarakis et al., 1998; Morin-Papunen et al., 1998).  
 
1.1.6.5 Surgical treatment 
The epidemic of obesity has spawned a second epidemic; bariatric surgery. In recent 
years,  there  has  been  a  dramatic  increase  in  the  number  of  bariatric  surgical 
procedures performed worldwide (Santry et al., 2005; Flum et al., 2005).
 Bariatric 
surgery  is  not  cosmetic  surgery.  It  is  major  gastrointestinal  surgery  performed  in 
extremely large patients whose obesity putting them at risk for complications and 
death, both from the medical problems associated with obesity and from the surgery 
itself. In a meta-analysis it was shown that surgery is more effective than non-surgical 
treatment for weight loss and control of some co-morbid conditions in patients with a 
BMI  of  40  kg/m2  or  greater  (Maggard  et  al.,  2005).  Surgical  treatment
 of  severe 
obesity  also  appears  to  be  cost-effective  by  eliminating
  use  of  medications  and 
absenteeism from work in patients who
 were previously morbidly obese (Martin et al., 
1995).  The  1991  National  Institutes  of  Health  Consensus  Development
  Panel 
published the recommended criteria for patient selection for surgical treatment shown 
below (Gastrointestinal surgery for severe obesity, 1992). 
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Criteria for Patient Selection 
 
·  Body weight
 100% above ideal weight  
 
·  BMI  40 kg.m
-2 
 
·  BMI  35 kg.m
-2 with medical
 co-morbidities 
 
·  Failure of non-surgical attempts at weight reduction  
 
·  Absence
 of endocrine disorders that can cause morbid obesity  
 
·  Psychological
 stability
  
 
·  Absence of alcohol and drug abuse 
  
·  Understanding of
 how surgery causes weight loss
  
 
·  Realization that surgery itself
 does not guarantee good results
  
 
·  Preoperative psychological
 evaluation for selected patients 
 
1.1.6.5.1 Types of surgery 
Bariatric surgery has continually evolved since its sporadic and tentative introduction 
in the 1950s. The first bariatric procedure, preceded by animal studies, subsequently 
presented to a recognized surgical society and published in a peer reviewed journal, 
was that of Kremen and associates in 1954, presenting a jejunoileal bypass (Kremen 
& Linner, 1954). Broadly speaking there are two types of surgery; malabsorptive and 
gastric  restrictive  surgery.  The  jejunoileal  bypass  (JIB)  and  its  more  recent 
modification,  biliopancreatic  diversion  (BPD)  and  biliopancreatic  diversion  with 
duodenal  switch  (DS),  are  classified  as  primarily  malabsorptive  procedures,  the 
gastroplasties  (horizontal,  vertical  and  vertical  banded  gastroplasty,  VBG)  are 
restrictive  as  is  laparoscopic  gastric  banding.  Roux-en-Y  gastric  bypass  (RYGB) 
represents  a  combination  of  these  two  mechanisms  (figure  1.1).  Malabsorptive 
procedures produce the greatest degree of weight loss, but can be associated with 
serious  and  potentially  life-threatening  metabolic  and  nutritional  complications. 
Restrictive procedures produce moderate degrees of weight loss and have the lowest 
incidence of metabolic and nutritional complications (Kral, 1992).  
 
   23 
 
 
 
Figure 1.1: Types of bariatric surgery A: Vertical-banded gastroplasty. B: Gastric 
banding  C:  Roux-en-Y  gastric bypass.  D:  Biliopancreatic  diversion  with  duodenal 
switch (Brolin, 2002). 
 
1.1.6.5.2 Benefits from surgical weight reduction  
All bariatric procedures have been able to achieve loss of more than 50% of excess 
weight (O’Brien et al., 2002; Buchwald et al., 2004; Maggard et al., 2005). Weight 
reduction  surgery  also  has  salutary  effects  on  obesity-related  hypertension  and 
cardiovascular  dysfunction.  Weight  loss  resulting  from  bariatric  surgery  has  been 
associated with significant improvement of left ventricular ejection fraction and lesser 
but  measurable  improvements  in  mean  blood  pressure,  cardiac  chamber  size,  and 
ventricular wall thickness (Alpert et al., 1985). The Swedish Obese Subject study 
however,  found  no  difference  in  blood  pressure  between  surgically  and  medically 
treated patients with hypertension 8  years postoperatively  (Torgerson  & Sjostrom,   24 
2001). In a four  year follow up study of several hundred patients who underwent 
Laparoscopic  Adjusted  Gastric  Banding  (LAGB)  elevated  serum  triglycerides  had 
returned to normal and HDL-cholesterol levels had risen to normal values (Dixon & 
O’Brien, 2002 (b)). Insulin resistance was reduced and beta-cell function improved 
(Dixon & O’Brien, 2002 (a); Dixon et al., 2003 (a)). Two-thirds of patients with type 
2  diabetes  return  to  having  no  clinical  evidence  of  the  disease,  and  have  normal 
fasting blood glucose, serum insulin and HbA1c levels without therapy. There is also 
a marked improvement or resolution of obesity-hypoventilation syndrome and sleep 
apnea following surgically induced weight loss (Charuzi et al., 1985; Sugerman et al., 
1988).  Other  reported  improvements  after  surgical  weight  reduction  have  been  in 
reflux oesophagitis (Dixon & O’Brien, 1999), depression (Dixon et al., 2003 (b)), 
asthma (Dixon et al., 1999), non alcoholic fatty liver disease (Dixon et al., 2004) and 
quality of life (Dixon et al., 2001). A randomised control study of 79 patients with 
mild  to  moderate  obesity  comparing  surgery  (LAGB)  with  medical  treatment 
(O’Brien et al., 2004) reported weight loss outcomes at 2 years of 71.5% excess body 
weight in the surgical group and 21.4% in the medical group. At 8 years follow-up, 
the Swedish Obesity Study reported the average weight loss of 20 kg among 251 
surgically treated patients and this was maintained. A 10-year follow-up data on 1703 
patients found those treated with surgery to have maintained their weight loss (16.1% 
decrease) contrary to ones on medical therapy (1.6% increase) (Sjostrom et al., 2000; 
2001). 
 
1.2  ADIPOSE TISSUE 
Obesity is defined by an excess of adipose tissue and in recent years this tissue has 
become a focus of intense study. 
 
1.2.1  Depot variations in adipose tissue 
Although the distribution of adipose tissue is significantly influenced by gender and 
obesity but it is unclear why some individuals gain relatively more upper body fat, 
and especially, visceral fat. Visceral fat mass is more closely correlated with obesity-
associated pathology than overall adiposity (Peiris et al., 1988; Stolk et al., 2003; 
Dipietro et al., 1999). Goodpaste et al. showed in a cross-sectional study of 3035 
subjects that the distribution of body fat, measured with CT scan, was independently 
associated with the metabolic syndrome in older men and women, particularly among   25 
those  of  normal  body  weight  (Goodpaste  et  al.,  2005).  Interestingly  abdominal 
liposuction  in  a  study,  had  not  significantly  improve  obesity-associated  metabolic 
abnormalities (Klein et al., 2004 (b)). However in another study when obesity surgery 
was performed with omentectomy significant improvement was seen in the metabolic 
profiles of the patients (Thörne et al., 2002). Cultured pre-adipocytes from omental 
fat,  obtained  from  people  with  severe  obesity,  have  a  reduced  capacity  for 
differentiation (Tchkonia et al., 2002) and proliferation (van Harmelen et al., 2004) 
but are more susceptible to apoptosis (Niesler et al., 1998; PaPineau et al., 2003) than 
pre-adipocytes  from  subcutaneous  abdominal  fat.  This  implies  a  site-specific 
regulation  of  pre-adipocyte  number.    The  release  of  adipokines  also  varies 
significantly  between  the  depots  and  this  suggests  that  the  endocrine  function  of 
human adipose tissue as a metabolic organ is subject to regional variations. Adipose 
tissue is therefore a heterogenous metabolic organ (Arner, 1998) but the mechanism 
in  which  visceral  obesity  links  to  adverse  outcomes  is  not  clear.    Montague  & 
O’Rahilly have suggested the anatomical site and venous drainage of visceral adipose 
tissue and possible differences in the adipocytes’ biology amongst few other possible 
explanations (Montague & O’Rahilly, 2000). 
 
1.2.2  Functions of adipose tissue  
1.2.2.1 Storage  
Adipose tissue is the main site of energy storage in mammals and birds. Fat, in the 
form of triacylglycerols, is deposited in the adipocytes and in addition to being an 
efficient  store  of  excess  energy  also  provides  thermal  and  mechanical  insulation. 
Adipocytes have a central role in the deposition and release of fatty acids. (Mohamed-
Ali et al. 1998; Fruhbeck et al. 2001; Trayhurn & Beattie, 2001). Adipocytes and the 
adipose tissue are able to dramatically change its size in accordance with changing 
metabolic needs. This ability gives the tissue an almost unlimited capacity for growth, 
making it perhaps the only tissue in the body with the ability to so drastically increase 
its size without an underlying transformed cellular phenotype.   
 
1.2.2.2 Adipogenesis 
Mature  adipocytes  differentiate  from  preadipocytes,  which  are  present  in  the 
stromavascular fraction  and can be recruited throughout adult life  (Ailhaud et al., 
1992). This phenomenon seems to be reversible, and several reports describe the de-  26 
differentiation of mature adipocytes into a preadipocyte state (Negrel et al., 1985; Ron 
et al., 1992). The fat cell number reflects the balance of preadipocyte proliferation, 
differentiation and apoptosis (Tchoukalova et al., 2004). Adipogenesis results from 
the transcriptional activation and
 expression of adipocyte genes in fibroblast-like cells 
determined for preadipoctyes. Preadipocytes must receive an appropriate combination 
of mitogenic
 and adipogenic signals to continue the differentiation process, leading to 
the progressive acquisition of the morphological
 and biochemical characteristics of 
the mature adipocyte.  
 
1.2.2.3 Lipolysis 
In times of fasting, tissues such as cardiac and skeletal muscle, and the liver, require 
substrate for energy production. Adipocytes are able to respond to these requirements 
by hydrolysing triglyceride into its component glycerol and fatty acids. Fatty acids are 
then free to diffuse out of the cell to be transported to where required. Stimulation of 
lipolysis is caused by many effectors, including catecholamines, prostaglandins and 
cytokines  such  as,  TNFa,  IL-1,  IFNa,  IFNb  and  IFNg.  Conversely,  glucose  and 
insulin are able to inhibit lipolysis. In addition to the release of glycerol and fatty 
acids, as a result of metabolic activity, the adipose tissue has now been shown to be 
secretory organ.  
 
1.2.2.4. Adipose tissue as a secretory organ 
Production of signalling products places adipocytes among secretory cells. In 1985, 
Kelly suggested two pathways for the release of secretory products; regulated and 
constitutive pathways (Kelly, 1985). In the regulated pathway secretory products are 
stored in a secretory granule. These granules remain in the cytoplasm until stimuli e.g. 
neural or hormonal stimuli trigger the release of the products. The granule’s half-life 
is hours to days and processing of precursors can occur in them. On the contrary in 
constitutive pathway, products are synthesised and packaged into membrane-limited 
vesicles in the Golgi apparatus and are rapidly released via exocytosis. There is no 
processing of the precursors, no storage and no regulation of their release. In some 
cells both pathways exist for the same product (Stachura & Frohman, 1975; Moore et 
al,  1983).  The  release  of  secretory  products  from  adipose  tissue  seems  to  be 
predominantly via constitutive release (figure 1.2). In lean men body fat mass is 10-
12% and in women 15-19%. This constitutive release of products is of paramount   27 
importance in obese and morbidly obese subjects who have a body fat mass ranging 
between  40-65%.  In  these  individuals,  organs  are  surrounded  by  large  amount  of 
adipose tissue and are chronically exposed to their secretions over years. 
 
 
Figure 1.2: Acute and chronic cytokine release. (a) Stimuli such as infection or 
exposure  to  inflammatory  stimuli  such  as  lipopolysaccharide  (LPS)  and  exercise 
results in an acute cytokine release and is mediated by immune and skeletal muscle 
cells,  respectively.  Cytokine  levels  rise  sharply  (50-100  fold)  for  a  short  period 
(hours). (b) Basal cytokine release increases with age and is higher in obese than lean 
individuals. The cytokine levels are much lower in obesity than those seen during 
infection  and  exercise  however  they  are  permanently  elevated  due  to  constitutive 
release from the excess white adipose tissue. (Mohamed-Ali et al., 2005) 
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1.2.2.5 Adipose tissue and adipokines 
The apparent simplicity of adipose tissue, both histologically and metabolically, with 
triacylglycerols constituting more than 85% of the tissue weight and there being only 
a ‘thin skim’ of cytoplasm between the fat droplet and the plasma membrane, it is 
unsurprising that the tissue had been regarded as essentially limited in function to 
lipid synthesis and breakdown (Trayhurn, 2005). Quantitatively, the most important 
secretory  product  of  adipocytes  is  fatty  acids.  The  tissue  also  releases other  lipid 
moieties, such as cholesterol, retinol, steroid hormones and prostaglandins (Trayhurn 
& Beattie, 2001). These substances are, however, not synthesized de novo within fat 
cells,  although  certain  steroid  transformations  can  take  place.  The  significance  of 
adipose tissue as an endocrine organ first surfaced in 1994 with the ground-breaking 
discovery of leptin (Zhang et al. 1994). Following research and analysis of expressed 
genes in adipose tissue has revealed that adipocytes produce and secrete a variety of 
bioactive substances, named adipokines. 
The diversity of the adipokines, both in terms of protein structure and of function, is 
considerable.  The  group  includes  classical  cytokines  (e.g.  TNF-α,  IL-6),  growth 
factors (e.g. transforming growth factor-b), proteins of the alternative complement 
system  (e.g.  adipsin,  acylation-stimulating  protein),  proteins  involved  in  vascular 
homeostasis (e.g. plasminogen activator inhibitor-1, tissue factor), the regulation of 
blood  pressure  (angiotensinogen),  lipid  metabolism  (e.g.  cholesteryl  ester  transfer 
protein,  retinol-binding  protein),  glucose  homeostasis  (e.g.  adiponectin)  and 
angiogenesis  (e.g.  vascular  endothelial  growth  factor),  as  well  as  acute-phase  and 
stress responses (e.g. haptoglobin, metallothionein) (Trayhurn, 2005). Tissue culture 
studies have indicated, that adipocytes directly signal to other tissues such as skeletal 
muscle and the adrenal cortex (Dietze et al., 2002; Ehrhart-Bornstein et al., 2003). 
There is also, in particular, a distinct cross talk between adipocytes and the brain 
through leptin and the sympathetic nervous system (Rayner & Trayhurn, 2001).  
 
1.2.3  Adipose tissue and inflammation 
The issue of inflammation is one of the most important developing areas in obesity 
and  the  emergence  of  the  concept  that  obesity,  like  diabetes,  is  characterized  by 
chronic low-grade inflammation (Yudkin et al., 1999; Bastard et al., 2000; Das, 2001; 
Festa et al., 2001; Engstro¨m et al., 2003). An increasing number of adipokines are   29 
directly linked to inflammation and the inflammatory response, mainly divided in to 
three categories as seen in figure 1.3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Adipokines related to inflammation. TGFβ: transforming growth factor 
b;  MCP-1:  Monocyte  Chemoattractant  Protein-1;  MIF:    Macrophage  migration 
Inhibitory  Factor;  PAI-1:  Plasminogen  Activator  Inhibitor-1;  NGF:  Nerve  Growth 
Factor;  VEGF:  Vascular  Endothelial  Growth  Factor;  Miscell:    miscellaneous 
(Trayhurn, 2005). 
 
The basis for this view is that the circulating level of several markers of inflammation, 
such  as  IL-6,  C-reactive  protein  and  haptoglobin,  are  elevated  in  obesity  and  are 
reduced with weight loss (Yudkin et al., 1999; Festa et al., 2001; Chiellini et al., 
2004).  Given  that  adipose  tissue  secretes  a  wide  range  of  inflammation-related 
proteins, it is probable that it is the source of at least some of the increase in these 
factors  in  obese  subjects.  A  key  hypothesis  is  that  adipose  tissue-derived 
inflammatory  factors  may  play  a  causal  role  in  the  development  of  the  insulin-
resistance and hence lead to metabolic syndrome (Hotamisligil, 2003; Yudkin, 2003). 
There is increasing support for such a concept and both the circulating levels and 
adipose  tissue  expression  of  several  adipokines  are  increased  in  obese  subjects, 
including  leptin,  plasminogen  activator  inhibitor-1,  IL-6,  TNF-α  and  haptoglobin 
(Considine et al., 1996; Ostlund et al., 1996; Mohamed-Ali et al., 1997 (a); Alessi et 
al., 2000; Bastard et al., 2000; Chiellini et al., 2004). In contrast, the production and 
circulating level of adiponectin, which has been reported to have an anti inflammatory 
effect (Yokota et al., 2000), is reduced in obesity (Arita et al., 1999; Hotta et al., 
2000). Obesity is also associated with increased macrophage infiltration of adipose 
tissue,  and  these  macrophages  may  be  an  important  component  of  the  chronic 
inflammatory response playing a crucial role in the development of insulin resistance   30 
(Neels & Olefsky, 2006). The reason for this chronic inflammatory response is not 
clear. One of the hypotheses is that the trigger for this inflammation is the hypoxia 
within clusters of adipocytes remote from the vascular supply in the expanding tissue 
(Trayhurn  &  Wood,  2004).  Hypoxia  leads  to  the  expression  of  hypoxia-inducible 
factor-1a,  which  when  combined  with  hypoxia-inducible  factor-1b  forms  the 
transcription factor hypoxia-inducible factor-1. In turn the transcription of a number 
of  genes,  including  those  encoding  the  GLUT1  facilitative  glucose  transporter, 
glycolytic enzymes, such as lactate dehydrogenase, and inflammation-related proteins, 
has  been  shown  in  several  tissues  to  be  stimulated  during  hypoxia  through  the 
medium of hypoxia-inducible factor-1 (Wenger et al., 2002). 
 
1.3  SPECIFIC ADIPOSE TISSUE DERIVED FACTORS 
1.3.1  RANTES 
RANTES is made up of 68 amino acids and is a member of the chemotactic cytokine 
family. It recruits, activates and co-stimulates T cells and monocytes and so plays a 
role in immuno-regulatory and inflammatory processes (Luster, 1998; Gerhardt et al., 
2001). RANTES binds to specific receptors in the G-protein coupled receptor family, 
namely  CCR1  and  CCR5  (Appay  &  Rowland,  2001),  however  the  mechanisms 
through which it activates leukocytes have yet to be elucidated. It appears that its 
function is dependant on its concentration. At low concentrations, RANTES acts in a 
monomeric,  or  dimeric,  form  directly  on  its  specific  receptor,  whereas  at  high 
concentrations, it self-aggregates to form a multimer which interact with cell-surface 
glycosaminoglycans
 (Appay et al., 1999). Its ability to self-aggregate is crucial in the 
activation and recruitment of leucocytes, as monomers have no effect, even though 
they are able to activate the G-protein coupled receptor. RANTES has therefore been 
implicated as a particular feature of inflammation, and its expression has been shown 
to  increase  in  a  number  of  imflammatory  conditions  such  as  allogenic  transplant 
rejection, atherosclerosis, arthritis, atopic dermatitis, inflammatory airway disorders 
like  asthma,  delayed  hypersensitivity  reactions,  glomerulonephritis,  endometriosis, 
certain neurological disorders, such as Alzheimer’s, and certain malignancies (Appay 
&  Rowland,  2001).  Following  the  discovery  that  RANTES  was  also  secreted  by 
adipose  tissue  (Xu  et  al.,  2003),  its  role  in  obesity  and  its  co-morbidities  has 
subsequently  been  the  subject  of  intense  research
  (Wu  et  al.  2007).  Circulating 
RANTES levels have been shown to be higher in the pre-pubertal obese, compared to   31 
the lean, individuals (Economou et al., 2004) as well as in subjects suffering from 
cardiovascular disease
 (Parissis et al., 2002). There was an association between the 
plasma RANTES levels and the cardiovascular risk factors, such as elevated serum 
triglycerides and a high waist-hip ratio
 (Koh et al., 2008). It is known that CCR5 is 
expressed  in  human  culture  adipocytes  and  was  present  on  the  cell  surface  of 
adipocytes in subcutaneous tissue (Gerhardt et al., 2001). Antagonism or knockout of 
the  RANTES  receptor  (CCR5)  has  seemed  to  reduce  the  development  of 
atherosclerosis in mice (Veillard et al., 2004; Braunersreuther et al., 2007). In contrast, 
up-regulation of RANTES and its receptors has been reported in adipose tissue in 
human obesity and has been associated with increased systemic inflammation (Huber 
et al., 2008). Wu et al. found higher RANTES and CCR5 mRNA levels in obese 
compared to lean mice but this increase was more pronounced in males. RANTES 
expression in males was also higher in the obese mice but this difference was not 
apparent in females.  In  addition, authors demonstrated that visceral adipose tissue 
exhibits higher levels of RANTES and CCR5 mRNA than subcutaneous adipose of 
morbidly obese humans and that unlike IL-6 and MCP-1, RANTES is derived from 
both the stromavascular and adipocyte sections, but that this too was gender-specific 
and higher in male individuals. These findings have lead to the belief that RANTES 
may contribute to the inflammatory infiltration characterised in obesity.  
 
1.3.2  Adiponectin  
Adiponectin is made up of 30-kDa polypeptide and was identified by four different 
groups in mid 90s, using different methods. Adiponectin undergoes hydroxylation and 
glycosylation post translation. The isoforms then form trimers and polymers, which 
then form low molecular weight (LMW), middle molecular weight (MMW) and high 
molecular weight (HMW) compounds (Pajvani et al., 2003; Waki et al., 2003). These 
forms  of  adiponectin,  contrary  to  the  monomers,  are  found  in  the  circulation 
(Chandran et al., 2003). There are two adiponectin receptors, adipoR1 and adipoR2. 
AdipoR1 is expressed primarily in the muscle and adipoR2 in the liver (Yamauchi et 
al., 2002). Therefore as well as circulating levels of adiponectin and its isoforms, its 
receptor subtypes also play a role in the effects exerted. Plasma adiponectin levels is 
higher in female suggesting a possible regulation by sexual hormones (Nishizawa et 
al., 2002; Combs et al., 2003; Xu et al., 2005) and increase with age (Adamczak et al., 
2005).  This  adipokine  circulates  at  high  levels  (3-  30  µg/ml)  compared  to  other   32 
adipokines, such as leptin with levels in the nanogram per milliliter range (Chandran 
et al., 2003; Fantuzzi, 2005). Adiponectin has a major role in energy homeostasis and 
inflammation (Lyon et al., 2003). It’s known to have anti-inflammatory effects such 
as reducing the activity and production of TNF-α (Masaki et al., 2004), inhibiting 
production of IL-6 and induction of IL-10 and IL-1 receptor antagonists, which are 
anti-inflammatory  cytokines  (Kumada  et  al.,  2004;  Wolf  et  al.,  2004;  Wulster-
Radcliffe et al., 2004).  
Contrary  to  other  adipokines,  adiponectin’s  expression  and  circulatory  levels  are 
decreased  as  BMI  increases.  There  was  also  a  negative  correlation  between 
adiponectin levels and insulin resistance and type 2 diabetes with reduced plasma 
levels found in conditions associated with insulin resistance such as cardiovascular 
disease (Kumada et al., 2003; Pischon et al., 2004) and hypertension (Ouchi et al., 
2003; Adamczak et al., 2003). In fact low adiponectin levels have been shown to be 
independently  associated  with  metabolic  syndrome  (Matsushita  et  al.,  2006).  The 
exact  mechanism  of  action  and  association  with  insulin  sensitivity  is  not  clear. 
However  adiponectin  has  been  shown,  in  the  skeletal  muscle,  to  increase  the 
expression  of  Acyl-coenzyme  A  oxidase  and  hence  the  combustion  of  fatty  acid, 
increase  the  uncoupling  protein  2  expression  which  helps  dissipate  energy  and 
increase CD36 that is involved in fatty acid transport (Yamauchi et al., 2001). All 
these help reduce tissue triglycerides and prevent insulin resistance (Shulman, 2000). 
It has also been shown to activate PPARα hence increase fatty-acid combustion and 
energy consumption and therefore reduce triglyceride in liver and muscle (Yamauchi 
et  al.,  2001)  as  well  as  activating  AMP  kinase  and  therefore  stimulating 
phosphorylation  of  acetyl  coenzyme-A  carboxylase,  fatty  acid  combustion  and 
glucose  uptake  (Yamauchi  et  al.,  2002).  Adiponectin  production  was  induced  by  
insulin-sensitizing drugs, such as the PPARg agonist, thiozolidinediones, as well as 
with weight loss (Yang et al., 2001; Weyer et al., 2001; Chandran et al., 2003; Diez & 
Iglesias,  2003).  However  the  regulation  of  this  adipokine  and  the  molecular 
mechanisms of its action are still not clear.  
 
1.3.3  MCP-1 
MCP-1 or CCL2, like RANTES, is also a member of the chemotactic cytokine family. 
Infusion  of  MCP-1  into  mice  increased  circulating  monocytes,  accumulation  of 
monocytes in collateral arteries and neo-intimal formation (Takahashi et al., 2003;   33 
van Royen et al., 2003). MCP-1 also plays an important role in the development of 
atherosclerosis as its expression is increased in atherosclerotic lesions (Yla-Herttuala 
et al., 1991; Takeya et al., 1993) and atheroma formation in hypercholesterolemic 
mice is reduced by inhibition of its expression or that of its receptor (Gu et al., 1998; 
Boring et al., 1998).  In apolipoprotein E-knock out mice that are prone to severe 
atheroma  formation this process was decreased when MCP-1 release  was blocked 
through transfection of an N-terminal deletion mutant in MCP-1 gene (Inoue et al., 
2002). MCP-1 was produced and released by the stromavacular fraction of adipose 
tissue, pre-adipocytes and isolated mature adipocytes (Gerhardt et al., 2001; Xu et al., 
2003). The release of MCP-1 from pre-adipocytes was triggered by levels of TNF-α 
secreted by adipocytes in obesity (Xu et al., 2003). While it was not clear whether the 
MCP-1 from endothelial cells or that from adipocytes attracts the macrophages into 
adipose tissue, its expression precedes the appearance of macrophage markers (Xu et 
al., 2003). Circulating MCP-1 levels are elevated in genetic (ob/ob mice) and diet-
induced  obese  mice  and  reduced  after  weight  loss  (Sartipy  &  Loskutoff,  2003; 
Takahashi et al., 2003). The mechanism of this process is not clear, however. It has 
been  suggested  that  over-nutrition  causes  a  metabolic  overload  with  increased 
demands  on  the  endoplasmic  reticulum  and  on  the  mitochondria  resulting  in  the 
release  of  pro-inflammatory  mediators  via  excess  production  of  reactive  oxygen 
species (Wellen & Hotamiligil, 2005). However it has also been shown that treating 
adipocytes with MCP-1 causes a decrease in lipid accumulation as well as stimulation 
of leptin secretion by post-transcriptional mechanisms (Sartipy & Luskutoff, 2003). A 
study  in  obese  children  and  adolescents  found  no  significant  correlation  between 
circulating MCP-1 and BMI (Glowinska & Urban, 2003). More recently it is found 
that the MCP-1 levels, both circulating and mRNA content of subcutaneous adipose 
tissue, are elevated in human obesity and are greater in visceral compared to that in 
subcutaneous tissue (Christiansen et al., 2005; Bruun et al., 2003). MCP-1 is also 
elevated in patients with type 2 diabetes mellitus and is associated with an increase in 
cardiovascular disease (Nomura et al., 2000; Piemonti et al., 2003). In adipocyte cell 
lines MCP-1 was found to decrease insulin-stimulated glucose uptake and insulin-
induced  insulin  receptor  tyrosine  phosphorylation  suggesting  an  important  role  in 
insulin resistance of adipose tissue (Gerhardt et al., 2001; Sartipy & Loskutoff, 2003). 
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1.3.4  IL-6  
IL-6 is  a 21 to 28 kDa protein, depending on  the cellular source  and  preparation 
(Hirano et al., 1986). IL-6 plays a central role in diverse host defense mechanisms 
such as the immune response, haematopoiesis, and acute-phase reactions (van Snick, 
1990) and along with other cytokines it represents an important frontline component 
of  the  body’s  defence  against  infection  or  tissue  damage  (Nicola,  1997).  Site  of 
production of IL-6 has been documented in a seemingly endless variety of cells namely 
fibroblasts (van Damme et al.,1987), endothelial cells (Corbel &  Melchers, 1984), 
keratinocytes  (Baumann  et  al.,  1984),  peripheral  blood  mononuclear  cells  (van 
Damme et al. , 1988), monocytes/macrophages (van Snick et al., 1986), T-cell lines 
(Hirano et al., 1985), mast cells (Plaut et al., 1989;  Hfiltner et al., 1989), a variety of 
tumor  cell  lines  (Hirano  et  al.,  1986),  and  more  recently,  adipose  tissue  and 
adipocytes (Mohamed-Ali et al., 1997 (a); Kern et al., 1995). In the steady state, IL-6 
was  usually  not  produced  constitutively  by  normal  cells,  but  its  expression  was 
readily induced by viral infections (Cayphas et al., 1987; Sehgal et al., 1988; Frei et 
al., 1989; Nakajima et al., 1989), lipopolysaccharide Lipase (LPL) (Nordan & Potter, 
1986), IL-1 (Shalaby et al., 1989), tumor necrosis factor-α , platelet-derived growth 
factor  (Kohase  et  al.,  1987),  IL-3  and  GM-CS.  However  not  all  cells  respond 
similarly  to  all  these  factors.  Chronic  IL-6  release  has  been  shown  to  inhibit 
monomeric LPL, an endogenous inhibitor of active (dimeric) LPL (Wallberg-Jonsson 
et al., 1996) and to stimulate lipolysis (Hauner et al., 1995; Path et al., 2001). This 
results in further production of free fatty acids and allows macrophages to take up 
triglycerides  and  become  atherogenic  foam  cells,  thus  promoting  atherosclerosis. 
Bruun et al. showed that sustained IL-6 release can inhibit adipose tissue expression 
of adiponectin (Bruun et al., 2003; Clarke & Mohamed-Ali et al., 2004). Furthermore, 
IL-6 can stimulate fibroblasts to differentiate into adipocytes (Kajkenova et al., 1997). 
The IL-6 expressed and released by adipose tissue (Kern et al., 1995; Mohamed-Ali et 
al., 1997 (a)) can influence endothelial function (Bhagat & Balance, 1997) and induce 
endothelial expression of chemokines and adhesion molecules (Romano et al., 1997) 
which are central in the early stages of the atherogenetic process (Jang et al., 1994). It 
has been shown that the production of IL-6, as well as its systemic concentrations, 
increase with adiposity (Mohamed-Ali et al., 1997 (a)) and also decrease with weight 
loss  (Dandona  et  al.,  1998;  Bastard  et  al.,  2000).  There  was  also  a  difference  in   35 
amount of production from different adipose tissue depots, with in vivo and in vitro 
studies suggesting a greater contribution from visceral than subcutaneous fat (Fried et 
al., 1998, Fontana et al., 2007). Insulin resistance in obesity may be directly caused 
by increased IL-6 as this cytokine has been shown to impair insulin signalling in vitro 
(Hotamisligil  et  al.,  1996).  Subsequently,  during  sustained  adiposity,  insulin 
resistance becomes a maladaptive consequence of obesity 
 
1.3.5  Leptin 
Leptin  has  revolutionized  the  study  of  adipose  tissue.  Discovery  of  leptin,  largely 
produced by adipocytes, reclassified the adipose tissue as an endocrine organ. Leptin 
is a 16 kDa peptide which has a cytokine-like structure (Zhang et al., 1994; Gaucher et 
al., 2003).  Its  receptor is a member of the  gp130 class  I cytokine  receptor family 
(Baumann et al., 1996). Consequently, leptin was occasionally grouped with the more 
traditional cytokines, such as IL-6 and TNF-α. Leptin is encoded by the ob gene and is 
expressed  predominantly  in  adipose  tissue,  in  correlation  with  the  amount  of  fat 
present in adipocytes, with the larger, more lipid engorged cells secreting more leptin 
(Friedman & Halass, 1998). It has been shown to have a role in a range of processes 
including the regulation of appetite and energy expenditure, glucose homeostasis, bone 
formation, regulation of puberty and reproduction, immunity and inflammation (Rajala 
& Scherer, 2003). It was present in the circulation and cerebrospinal fluid. It crosses 
the blood-brain barrier and binds to receptors in the hypothalamus, where it stimulates 
anorexigenic peptides, and inhibits orexigenic peptides, thus regulating food intake 
(Ronti et al., 2006). Leptin also acts on skeletal muscle, pancreas, liver and adipose 
tissue (Rajala & Scherer, 2003). Mice with leptin (ob/ob) or leptin receptor (db/db) 
gene  mutations  were  massively  obese,  infertile  and  insulin  resistant  (Zhang  et  al., 
1994; Fantuzzi, 2005). Similarly, in very rare cases of human leptin deficiency due to 
chromosomal mutations, individuals were morbidly obese, hyperphagic and did not 
undergo normal sexual maturation (Clement et al., 1998; O’Rahilly et al., 2003). In 
both  cases,  leptin  administration  led  to  dramatic  weight  loss,  improved  insulin 
sensitivity  and  resolution  of  hypogonadism.  Leptin  treatment  was,  however,  less 
effective  in  the  majority  of  obese  patients  because  human  obesity,  in  the  main,  is 
associated with leptin resistance (Bakker et al., 2004). It is unclear as to the cause of 
this resistance and its molecular basis, but, it has been suggested that it could be the 
result of impaired leptin transport through the blood brain barrier and/or signalling   36 
defects of the leptin receptor in the hypothalamus (Farooqi et al., 2002). Leptin is 
involved in regulating many inflammatory and immune processes (Fantuzzi, 2005). 
Plasma leptin levels are increased in diet induced obesity (Li et al., 1997) and correlate 
with BMI (Maffei et al., 1995) and percentage body fat (Considine et al., 1996) as 
well increasing with age. Leptin was expressed in significantly larger amounts in the 
subcutaneous  tissue  compared  to  visceral  depots  (Lefebvre  et  al.,  1998).  It  also 
resulted  in  inhibition  of  the  action  of  insulin  and  lipogenesis,  and  stimulation  of 
lipolysis (Wang et al., 1999; Aprath-Husmann et al., 2001). The effect of leptin on 
insulin is not clear, however. Some studies have shown a correlation between leptin 
and  insulin  resistance  (Zimmet  et  al,  1996;  Girard,  1997),  some  have  found  have 
found no relation (Mohamed-Ali et al., 1997 (b)) and others have shown leptin to be 
an anti-diabetic agent (Sivitz et al., 1997).  
 
1.4  REGULATION OF ADIPOSE TISSUE DERIVED FACTORS 
The molecular pathways behind the constitutive release of these adipokines and their 
regulation are poorly understood.  These signals produced by adipose tissue potentially 
mediate adverse cardiovascular effects, modulate prostaglandins/Interleukins release, 
insulin resistance and endothelial NO bioavailability (Clarke & Mohamed Ali, 2004). 
Many adipokines are cytokines with ‘immunological’ origin; and cytokines in immune 
cells are often regulated by the COX or NOS pathways. Therefore these two pathways 
are reviewed in greater detail in the following sections.  
 
1.4.1  Prostaglandins and COX pathway  
Prostaglandins are formed from arachidonic acid. Arachidonic acid is released from 
membrane  phospholipids  in  response  to  various  physiological  and  pathological 
stimuli by the action of phospholipaseA2 which is followed by the actions of COX 
and the respective synthases (Narumiya et al., 1999) (figure 1.3). COX-1 and COX-2 
are its two closely related forms. COX-1 is predominantly constitutively released and 
is expressed throughout the body and provides certain homeostatic functions, such as 
maintaining normal gastric mucosa, influencing renal blood flow, and aiding in blood 
clotting by abetting platelet aggregation (Turini & DuBois, 2002). In contrast, COX-2 
is  the  inducible  form  (Hla  &  Neilson,  1992)  and  is  expressed  in  response  to 
inflammatory and other physiologic stimuli and growth factors and is involved in the 
production of those prostaglandins that mediate pain and support the inflammatory   37 
process.  The  two  isoforms  are  different  in  their  amino  acid  sequence  of  the 
arachidonic acid binding site and this difference allows for their selective inhibition 
(Marnett & Kalgutkar, 1999). Release of prostanglandins from rat adipose tissue was 
first noted in 1968 (Shaw & Ramwell, 1968). IL-6 is also produced by adipose tissue  
and especially in obesity a significant portion of systemic IL-6 may be adipose tissue 
derived (Mohamed-Ali et al., 1997 (a)). It may be that constitutive IL-6 release from 
the expanded fat mass leads to its chronic elevation in this condition. It has been 
shown  that  the  treatment  of  epithelial  cells  with  prostaglandinE2  (PGE2)  caused  a 
dose-dependent increase in IL-6 release (Tavakoli et al., 2001) and that both PGE2 
and  carbacyclin,  an  prostacyclin  analogue,  increased  IL-6  release  from  human 
placenta (Turner et al., 2004) .  In our group (unpublished results)  IL-6 release in 
primary human adipose tissue cell cultures was increased after treatment with PGE2, 
PGI2, PGD2 and especially with carbacyclin, an IP receptor agonist. Understanding 
the molecular mechanisms regulating adipose IL-6 secretion could lead to dietary and 
pharmacological  strategies  to  modulate  this  cytokine  in  obesity  associated 
pathologies. 
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Figure  1.4:  The  COX  pathway:  IL-6  release  occurs  through  changes  in  the 
COX/Prostaglandin  axis.  Various  synthases  convert  PGH2  into  the  corresponding 
prostaglandins.  PGE2  signals  via  EP  receptors  and  PGI2  via  IP  receptors.  IL-6 
secretion is regulated via receptors that are mediated by elevation in cAMP (EP2, 4 
and IP).  PGI2S: Prostacyclin synthase. PGE2S: ProstaglandinE2 Synthase.  
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1.4.2  NOS Pathway  
1.4.2.1 NO 
NO  is  synthesized  from  L-arginine  by  NOS.  It  has  a  cruicial  role  in  endothelial 
function and relaxation. Endothelium-derived NO regulates arterial tone through a 
dilator action on vascular smooth muscle cells. Studies demonstrating increased blood 
pressure in animals lacking endothelial NOS provide evidence for a role of NO in the 
regulation  of  arterial  pressure  (Huang  et  al.,  1995).  Endothelial  dysfunction 
understandably  is  an  early  abnormality  in  the  pathogenesis  of  atherosclerosis. 
Alterations of the NOS pathway and impairment of NO-dependent vasodilation has 
been  linked  to  several  well-known  atherogenic  risk  factors,  including 
hypercholesterolemia, hypertension, type 2 diabetes, smoking, and ageing (Boger et 
al., 1996). Reduced NO and therefore endothelial dysfunction can arise because of 
low NO bioavailability, enhanced NO degradation triggered by high oxidative stress, 
low availability of the substrate of NO synthase, L-arginine, or because of an increase 
in  the  endogenous  NO  inhibitors  such  as  asymmetric  dimethylarginine  (ADMA). 
Recently, increased focus has been on ADMA and there are reports that the plasma 
concentrations of ADMA are elevated in human disease states. 
 
1.4.2.2 Asymmetrical Dimethyl Arginine 
This  amino  acid  is  structurally  similar  to  L-arginine  with  which  it  competes  as 
substrate for NOS (Kielstein & Zoccali, 2005). The arginine analogues identified to 
date include N
G-mono-methyl-L-arginine (L-NMMA), N
G, N
G-di-methyl-L-arginine 
(asymmetric  dimethyl-arginine;  ADMA)  and  NG,N′G-dimethyl-L-arginine 
(symmetric di-methyl-arginine; SDMA). The asymmetrically (L-NMMA and ADMA), 
but  not  the  symmetrically  methylated  arginine  residues  (SDMA),  are  competitive 
inhibitors of the NOS enzymes (Leiper, 2005). In pre-contracted endothelium-intact 
rat aortic rings, ADMA has been shown to cause dose dependent increases in tone. 
ADMA was able to raise blood pressure in guinea-pigs and reduce resting forearm 
blood flow. Thus, it was postulated that ADMA, which was identified as circulating in 
human plasma at a concentration ten times greater than that of naturally occurring L-
NMMA,  might  act  as  an  important  endogenous  regulator  of  the  L-arginine/NO 
pathway and/or arginine-handling enzymes in vivo (Vallance et al., 1992). Protein 
methylation is a post-translational modification (Clarke, 1993; Aletta et al., 1998) and   40 
is  catalysed  by  a  family  of  enzymes  termed  protein-arginine  methyltransferases 
(PRMTs). The genes encoding PRMTs have only been cloned in the last decade and 
their cellular functions are only beginning to be understood. McDermott observed that 
contrary to earlier belief (McDermott, 1976), ADMA was not fully excreted via urine 
but  was  hydrolysed  by  an  enzyme  named  N
G,N
G-dimethylarginine 
dimethylaminohydrolase (DDAH) (Ogawa et al, 1989). DDAH hydrolyse ADMA and 
L-NMMA, not SDMA, to give citrulline and dimethylamine or monomethylamine, 
respectively.  
ADMA is raised in a variety of conditions associated with high cardiovascular risk, 
such  as  in  familial  hypercholesterolemia  and  essential  hypertension,  and  was 
particularly evident in patients with end-stage renal disease (Vallance et al., 1992; 
Zoccali et al., 2001). Overall, ADMA is emerging as a cardiovascular risk marker of 
primary importance (Zoccali, 2006) and as a potential target for interventions aimed 
at  reducing  atherosclerotic  complications.  Only  recently  studies  have  looked  at 
ADMA in obesity. Eid et al. has shown a close relationship between BMI and plasma 
levels of  ADMA  and the  L-arg/ADMA ratio, independent of other metabolic risk 
factors (Eid et al., 2004). Overweight and obese subjects had significantly elevated 
ADMA levels and lower L-arg/ADMA ratio compared to lean or normal individuals.  
 
1.4.2.2.1 ADMA, Insulin and endothelial dysfunction  
Obesity, hypertension, type 2 diabetes and dyslipidaemia are all commonly associated 
with  reduced  sensitivity  to  the metabolic  actions  of  insulin  (Pinkney  et  al.,  1997; 
Reaven, 1988). Although it is frequently assumed that the increased insulin secretion 
is  a  result  of  insulin  resistance,  there  appears  to  be  some  evidence  that 
hyperinsulinaemia may precede the development of insulin resistance, which can play 
a role in the pathogenesis of obesity (Penicaud et al., 1989; Le Stunff & Bougneres, 
1994; Rizza et al., 1985; Sigal et al., 1997). An association has been seen between 
insulin resistance and raised serum ADMA and treatment with an insulin-sensitizing 
drug,  Rosiglitazone,  enhanced  insulin  sensitivity  and  reduced  plasma  ADMA 
concentrations (Stuhlinger et al., 2002). It is now established that activation of the 
PPARg, by thiazolidinediones, induces differentiation of preadipocytes into mature fat 
cells leading to increased NEFA uptake and decreased plasma concentrations. This 
was often accompanied by a reduction in plasma glucose concentrations and oxidative   41 
stress. The mechanism for thiazolidinedione’s ADMA lowering effect (Stuhlinger et 
al., 2002), is not yet known. It could be mediated through a reduction in oxidative 
stress,  and/or  increased  DDAH  activity  and  hence  increased  ADMA  degradation 
(Chan  &  Chan,  2002).  Reduced  plasma  ADMA  levels  have  also  been  seen  with 
Metformin treatment in poorly controlled type 2 diabetic patients (Asagami et al., 
2002). Weight loss studies in insulin resistant obese individuals have shown plasma 
ADMA  concentrations  decreased  in  conjunction  with  improvement  in  insulin 
sensitivity after weight loss. However this was not evident in insulin sensitive obese 
subjects (Mclaughlin et al., 2006). This and other published literature suggest that 
insulin  resistance  is  the  cause  of  vascular  dysfunction  (Ferrannini  et  al.,  1987; 
Reaven, 1988; Russell et al., 1998; Pinkney et al., 1997;Hsueh et al., 1997; Jin & 
Bohlen, 1997). This hypothesis remains unproven. A study on diet-induced obese rats 
found markedly impaired arterial relaxation, mainly due to endothelial dysfunction 
and these defects occurred in the absence of significant insulin resistance suggesting 
endothelial dysfunction precedes insulin resistance (Naderali et al., 2001). 
 
1.5  AIMS OF THE STUDY 
The aim(s) of this study were to investigate the signals from adipose tissue in morbid 
obesity and explore some of the molecular mechanisms regulating adipokine secretion.  
Specific aims were to investigate: 
1)  in a cross-sectional study of morbidly obese individuals undergoing surgery, the: 
a)  in vitro release of RANTES, MCP-1, adiponectin, IL-6 and leptin,  
b)  site specific differences of adipokine secretion, including comparison of two 
visceral depots; omental fat and the gastric fat pad 
2)  components of the COX pathway and its role in IL-6 release from adipose tissue 
3)  components of  the NOS pathway and its association with indices of insulin 
sensitivity 
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2.1  RECRUITMENT 
Patients  undergoing  bariatric,  reflux  operations  or  cholecystectomy  were  recruited 
from Mr Majid Hashemi’s surgical outpatient clinic or identified from his operating 
lists at the Whittington NHS Hospital Trust. The inclusion and exclusion criteria were 
as shown below: 
Subject Inclusion Criteria 
·  Adults aged >= 21 years 
·  Obese subjects with BMI >28 kg.m
-2 
Subject Exclusion Criteria 
·  Current  treatment  with  aspirin,  NSAID’s,  steroids,  warfarin,  ACE  inhibitors, 
statins or other agents known to affect prostaglandin or cytokine synthesis  
·  Diabetes mellitus  
·  Coronary artery disease   
·  Connective  tissue  disease  or  other  inflammatory  conditions  likely  to  affect 
cytokine levels  
·  Malignancy or other terminal illness  
·  Severe uncontrolled hypertension  
·  Immunocompromised subjects 
·  Substance abuse or other causes or poor compliance 
 
All patients undergoing bariatric surgery were on liver shrinkage diet for 2 weeks 
prior to surgery and were advised to drink 2 liters of fluid daily. Patients were allowed 
to have: cheese, egg, mayonnaise, butter, meat, nuts, seed, salad, vegetables, herbs, 
stock cubes, lemon juice, artificial sweetners, and fizzy drinks. They were not allowed 
to have: alcohol, biscuits, chocolates, cakes, cereals, bread, pasta, rice, potato, sugar, 
pastry, pies, fruit juice, ice cream and tinned soup. The following foods were allowed 
in limited amounts: 1/3 pint of milk/yoghurt, three portions of fruit; 1 slice of melon, 
medium  bowl  of  strawberries,  orange,  apple,  small  banana,  pear,  peach,  100  g  of 
tinned fruit in natural juice and 1 portion of vegetables (2 tablespoons); sweetcorn, 
peas, green beans, kidney beans, baked beans. 
The patients recruited from clinic had the study explained and an invitation letter and 
information sheet provided to them.  Patients not seen in clinic, but planned to have 
one of the above procedures, were sent an invitation letter and information sheet by   44 
post. All patients were contacted after 48 hrs, in order to answer their queries and 
obtain their decision with regards to joining this study. The study had been approved 
by the Moorfields and Whittington Ethical Committee. 
 
Schematic of study design 
Screening  Identification of suitable patients from the clinic and theatre list 
Clinic/Telephone   Explanation  of  study,  answer  questions  and  issue  information 
sheet. 
Operation day  Consent was obtained. 
Medical history questionnaire was completed 
Anthropometric measurements were obtained  
Fasted blood were taken 
Intra-operatively,  subcutaneous,  omental  and  gastric  fat  pad 
biopsies were taken.  
 
Table 2.1: Schematic of study design. The recruitment, consent, measurements and 
samples taken from patients 
 
2.1.1  Medical history questionnaire 
Preoperatively a questionnaire was completed, detailing past medical history, drug 
history, social history and family history of heart disease or diabetes history, whether 
they had taken or were prescribed any medication recently.  
 
2.1.2  Anthropometric measures 
Random blood pressure and heart rate were measured by electronic blood pressure 
monitoring devices. Weight (in kg), height (in m), waist circumference (in cm) and 
hip  circumference  (in  cm)  were  measured  and  the  waist/hip  ratio  was  calculated. 
Waist  and  hip  measurements  were  made  by  plastic  measuring  tape.  BMI  was 
calculated by weight in kilograms divided by the square of height in metres. Body 
composition  was  measured  by  electrical  bioimpedence  analyzer  (Biostat,  Douglas, 
U.K.). This devise measured the impedance or resistance to the flow of a safe and 
low-level electric current through the body fluids and estimated fat and lean mass and 
body water as a percent of total body mass.  
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2.1.3  Fasting blood samples  
Fasting  blood  samples  were  used  for  measurement  of  serum  lipid  profile  (total 
cholesterol,  LDL-cholesterol, HDL-cholesterol and triglyvcerides), plasma glucose, 
plasma  insulin  and  adipokines.  HOMA-R  index  was  calculated  by  the  following 
formula: Glucose (mmol/l) x Insulin (MU/l) / 22.5 
 
2.1.4  Fat biopsy 
A small sample (2-4gms) of adipose tissue was obtained from the subcutaneous tissue 
of anterior abdominal wall and from two visceral fat samples: Omental and Gastric fat 
pad (figure 2.1), during the primary surgical procedure under general anesthetic. In 
some patients the gastric fat pad was not obtainable. 
 
 
Figure 2.1: Gastric Fat Pad (GFP). This fat depot is in proximity of the stomach 
and macroscopically looks different from omental fat.  
 
2.2  RNA 
2.2.1  RNA extraction 
Fat tissue obtained from the biopsies was stored in RNALater (Ambion, USA) and 
kept at -20°C until RNA extraction and analysis. 0.2 gram of fat was ground in a 
pestle and mortar while being kept frozen with liquid N2. The fat powder was placed 
in a 1.5 ml eppendorf tube and RNA extracted with the RNeasy kit (Qiagen, USA) as 
per manufacturer’s instructions. First step of this process was the addition of 1ml of 
QIAzol lysis buffer to the ground tissue and the mixture was left sitting for 5 minutes 
at  room  temperature.  Then  200µl  chloroform  was  added,  vigorously  mixed  by 
vortexing, left standing for 3 minutes at room temperature and spun at 13000 rpm, for 
15 minutes, at 4°C. The clear top layer was then separated and equal volume of 70% 
Stomach 
Gastric Fat Pad 
Liver 
Omental   46 
ethanol was added. The mixture was vortexed and pippetted in the RNeasy Mini Spin 
Column  provided.  The  column  was  spun  at  13000  rpm,  for  15  seconds,  at  room 
temperature.  The  flow  through  was  discarded  and  the  buffers  provided  were  next 
added to the column as per protocol: first with 700 µl of RW1 buffer, followed twice 
by 500 µl of RPE buffers. Each time the columns were spun at 13,000 rpm for 15 
seconds at room temperature and the flow through discarded. Then 50µl of nuclease 
free water was added to the column with a fresh collection tube. After a 2-minute spin, 
at 13000 rpm, at room temperature, RNA was collected and stored at -80°. For RNA 
extraction from stromavascular fraction or adipocytes, 10µl of nuclease free water 
was used to achieve higher RNA concentrations. 
 
2.2.2  cDNA synthesis 
The concentration and purity of isolated RNA was assessed by measuring the optical 
density  at  260nm  (OD260)  and  280  nm  (OD280).  The  Ultrospec  3000  analyser,  an 
UV/Visible spectrophotometer (Amersham pharmacia biotech, Uppsala, Sweden) was 
calibrated with nuclease free water. 5 µl of RNA sample was diluted in 55 µl of 
nuclease free water. The diluted sample was transferred into a crystal cuvette and 
placed  in  the  analyser,  which  calculated  the  OD260/OD280  ratio  and  the  RNA 
concentration of the sample in µg/ml. The purity of RNA preparation was assessed by 
the OD260/OD280 and ratios of 1.4 to 1.8 were considered acceptable. Samples were 
done in batches of ten, before the analyser was re-calibrated.  
cDNA was then synthesised from the RNA by using Taqman Reverse Transcription 
Reagents (Applied Biosciences, USA). Volume of RNA needed for obtaining 0.5 µg 
and the total reaction volume was calculated. Usual reaction volume was 25µl. Master 
mix was made up with dNTP, RNAse inhibitor, and random oligonucleotide primers, 
provided by the kit. Mixture was added up to the required volume with nuclease free 
water. Reverse transcriptase buffer was added during the last step. The mixture was 
heated at the following steps: 48 ºC for 30 seconds, 42 ºC for 2 minutes and 72 ºC for 
15 minutes. Samples were held at 4ºC, the cDNA stored at - 20° if necessary prior to 
PCR analysis.  
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2.2.3  Real-time rt-PCR analysis 
Specific  primer  sequences  for  Taq-man®  rt-PCR  analysis  were  purchased  from 
Qiagen, USA. Primers were diluted to 10 µM concentration. The volume of primer 
used was equivalent to 20 ng of template in each tube. For each primer, a mixture 
containing forward primer, reverse primer and nuclease free water was added to make 
up a total reaction volume of 20 µl.  Twenty µl of SYBR Green Master Mix (Applied 
Biosciences, USA) was added to each tube. Samples were run in triplicate with 10 µl 
total volume per well in 96-well rt-PCR plates. For each rt-PCR reaction, ß-Actin was 
used as the housekeeper gene.  
 
2.2.4  ct calculations 
Data were analysed according to Livak and Schmittgen for the relative quantification 
of real time rt-PCR data (Livak & Schmittgen, 2001). This method known as 2 -
  ct, 
calculates the relative changes in gene expression between two or more samples, in 
which one sample is nominated as baseline (or calibrator) and all remaining samples 
are expressed relative to this control. 
 
2.3  PROTEIN 
2.3.1  Protein extraction and Western Blot 
Fat  tissue  obtained  from  biopsy  was  placed  in  RNALater  and  stored  at  -20°until 
analysis. The tissue (0.2 gram) was ground, while being kept frozen with liquid N2 
and lysed in protein lysis buffer (1% Triton X-100, Tris-HCL, PH 7.6, 150 mM Nacl) 
supplemented  with  protease  inhibitors  at  100   M  (Boehringer  Mannhein,  Sussex, 
U.K.). The homogenate was centrifuged at 13,000 rpm at 4ºC for 15 minutes and the 
supernatant was recovered. The protein content was estimated with a kit from BioRad, 
U.K., and 25  g of total protein was separated for by SDS-PAGE electrophoresis with 
a 12.5% resolving gel and 5% stacking gel. Gels were blotted onto PVDF membranes 
and  blocked  with  5%  non-fat  dried  milk  and  probed  with  polyclonal  antibodies 
against human PGIS and α-tubulin. Polyclonal antibodies to PGI2S were purchased 
from Cayman Chemical (Ann Arbor, USA) and those to α-tubulin, used as control, 
were  obtained  from  Sigma  (Poole,  U.K.).  Secondary  antibodies  conjugated  to 
horseradish  peroxidise  were  from  Amersham  Bioscience.  Antigen-  antibody 
complexes  were  detected  by  chemiluminescence  with  an  ECL  kit  (Amersham   48 
Biosciences, U.K.) and blots exposed to high performance chemiluminescence film 
(Hyperfilm ECL, Amersham Biosciences).  
 
2.3.2  Cytokine Protein Array 
The assay was carried out as per manufacturer’s instructions (Proteome Profiler Array, 
Human Cytokine Array Panel A, R & D Systems, U.K.). Capture antibodies specific 
to thirty six cytokines/chemokines (mentioned below) were spotted in duplicate on 
nitrocellulose  membranes.  Each  membrane  was  incubated  for  1  hour  at  room 
temperature with blocking buffer (provided by the kit, # 895022); 350  l of organ 
culture supernatant were diluted in assay buffer (provided by the kit, # 895876) to a 
final volume of 1.5 ml and incubated with buffer containing biotinylated detection 
antibody  for  1  hour  at  room  temperature.  The  sample/antibody  mixture  was  then 
incubated with the membrane on a rocking platform at 4 
oC overnight. Following a 
wash  to  remove  unbound  material,  streptavidin-horseradish  peroxidase  and 
chemiluminescent  detection  reagents  (substrate  provided  by  the  kit)  were  added 
sequentially. Membranes were exposed to X-ray film (Amersham Hyperfilm ECL, 
GE Healthcare, U.K.) for up to 3 min. Films were scanned and quantified as pixel 
density using Adobe Photoshop. Signals from the negative control spots (background 
value) were subtracted from each spot. Positive control spots were assigned as 100% 
and other spots expressed relative to this. Spots with densities less than 10% of the 
positive controls were considered negative.   
The 36 cytokines were as follows:   
C5a, GCSF, CXCL1, CD54, IL-1RA, IL-6, IL-8, IL-13, IL-16, MCP-1, MIF, PAI-1, 
IP-10, RANTES, CD154, GM-CSF, CCL1, IFNγ, IL-1 α, IL-β, IL-2, IL-4, IL-5, IL-
10,  IL-12  p70,  IL-17,  IL-17E,  IL-23,  IL-27,  IL-32α,  CXCL-11,  CCL-3,  CCL-4, 
CXCL-12, TNF-α, soluble TREM-1. 
 
2.4  STROMAVASCULAR FRACTION EXTRACTION 
Fat  tissue  was  cleaned  from  vessels,  weighed  and  cut  into  small  pieces  with  fine 
scissors, digested with 0.2% collagenase in a shaking water bath at 37
oC, 100 rpm for 
1 hr. The mixture was homogenized and the stromal cells were separated from mature 
adipocytes by adding 2 ml of Di-isononyl phathalate and centrifuging at 2060 rcf, for 
15 minutes, at 4
oC. The adipocytes were separated, frozen in dry ice and stored at -
80°C.  The  supernatant  was  removed  and  1ml  of  serum  free  medium  (Cell-gro,   49 
Hyclone, USA) was added to the pellet (stromavascular fraction) and centrifuged at 
2060 rcf, for 2 minutes, at 4
oC. This process was repeated three times. The pellet was 
re-suspended in Cell-gro for 1 hr.  The volume of Cell-gro used for re-suspension 
depended on the size of the pellet. The samples were then frozen in dry ice and stored 
at -80°C.    50 
 
2.5  ORGAN CULTURE BATH 
2.5.1  Adipose tissue organ cultures  
The adipose organ cultures were set up with 0.2 gm of adipose tissue in 1 ml of 
serum-free media (Cell-gro, Hyclone, USA), incubated for 24 hours at 37
oC/5% CO2. 
The explant supernatants were then stored at -80° and used to estimate in vitro release 
of adipokines by ELISA. 
 
2.5.2  Incubation with COX inhibitors 
Adipose tissue from subcutaneous and omental depots were divided into seven 0.1gm 
samples.  Each  tissue  was  incubated  over  5  hrs  at  37
oC/5%  CO2  with  two 
concentrations of non-selective COX inhibitors (Aspirin 0.2 mM and 5.0 mM), two 
COX-1 selective inhibitors (NS-398 0.01 mM and 1.0 mM) and two selective COX-2 
inhibitors (Sc-560 0.01 mM and 1.0 mM) as well as a control sample incubated with 
only Cell-gro. Aspirin (acetylsalicylic acid) was obtained from Sigma (Poole, U.K.). 
NS-398 and SC-560 were purchased from Alexis Corporation (Nottingham, U.K.). 
Supernatant explants were then stored at -80°C. The cell culture supernatants were 
assayed for prostaglandins: PGE2 and 6-keto PGF1α (a stable metabolite of PGI2). 
The  prostaglandin  concentrations  were  determined  using  Prostaglandin  E2  (PGE2) 
Biotrak Enzyme-immunoassay system and 6-keto-Prostaglandin F1α (6-keto PGF1a) 
Enzyme-immunoassay Biotrak system (Amersham Biosciences, Little Chalfont, U.K.).  
 
2.6  ELISA 
2.6.1  Glucose, lipids, C-reactive protein, prostaglandins,  
Plasma glucose concentration was assayed with glucose oxidase reagent (Beckman, 
CA, USA).  
Serum  triglycerides  and  total  cholesterol  were  assayed  with  commercial  reagents 
(total-cholesterol:  Boehringer-Mannhein,  Sussex,  U.K.  and  triglycerides:  Roche 
Diagnostics, Herts, U.K.). HDL-cholesterol was measured by the same method after 
the low density lipoproteins were quantitatively precipitated out by the addition of 
phosphotungstic  acid  in  the  presence  of  magnesium  ions.  LDL-cholesterol  was 
calculated using the Friedwald formula (Friedewald et al., 1972).  
C-Reactive Protein (CRP) was measured by a latex-enhanced immuno-turbidimetric 
(agglutination) procedure. The turbidity of the anti-CRP antibody-latex was measured,   51 
which  related  to  the  concentration  of  CRP.  The  turbidity  was  measured 
photometrically at 340nm. 3 ul of serum samples was used.  CRP was measured on 
the Roche/Hitachi Modular PP analyser (leased 2002) using a Roche Tina-Quant CRP 
(Latex) turbidemetric kit (CRPLX code 3002039). Assay time was 10 minutes, at 
room temperature.  
Glucose, lipids and CRP assays were performed by Dr David Wickens at Chemical 
Pathology, Whittington Hospital (London, U.K.).  
 
2.6.2  Cytokines 
Plasma  and  explant  supernatant  levels  of  IL-6,  RANTES,  MCP-1,  leptin  and 
adiponectin were measured by 2-site ELISAs (R & D Systems, Oxon, U.K.). Insulin 
ELISA  kit  was  from  Mercodia  (Uppsala,  Sweden).  Human  plasma  IL-6 
concentrations were assayed with the high sensitivity ELISA with a limit of detection 
of 0.09pg/ml. All other ELISAs for the measurements of adipokine levels in culture 
supernatants or plasma were normal sensitivity with inter and intra-assay CVs less 
than 10% (R & D Systems, Oxon, U.K.).  
The following dilutions were necessary for assaying plasma and explant adipokine 
levels: 
  Serum  Explant 
IL-6  Neat  1/200 
MCP-1  1/5  1/50 
Adiponectin  1/100  1/50 
RANTES  Neat  Neat 
Leptin  1/100  1/20 
Insulin  Neat  - 
 
Table 2.2: Dilution of sample prior to assay by ELISA 
 
2.7  ADIPONECTIN (MULTIMERIC) EXTRACTION  
Serum  Multimeric  Adiponectin  was  assayed  with  “Alpco  diagnostic”  ELISA  kit 
(Salem, NH). With this assay, total adiponectin (total-Ad), high-molecular (HMW-
Ad), middle-molecular (MMW-Ad), high-medium-molecular (HMWMMW-Ad) and 
low-molecular weight adiponectin (LMW-Ad) fractions could be assessed. Samples 
were pre-treated with protease for measurement of a specific adiponectin multimere 
and  levels  were  determined  either  directly  or  indirectly.  Total-Ad,  HMW-Ad  and   52 
HMWMMW-Ad fractions were assayed directly. LMW-Ad values were obtained by 
subtracting the combined concentration of MMW-Ad and HMW-Ad from the total 
concentration. MMW-Ad values were obtained  by subtracting HMW-Ad from the 
concentration of HMWMMW-Ad. 
 
2.8  PROSTAGLANDIN EXTRACTION FROM ADIPOSE TISSUE 
Protein was extracted from adipose tissue as described above (section 2.3.1). 100 l of 
protein was diluted with 200 l of methanol and made up to 1ml with distilled H2O. 
The sample was acidified to pH 3.5 with 1 N HCL. Sep-Pak® Vac 3cc (500mg) C18 
cartridges (Waters, Elstree, U.K.) were preconditioned by washing the column with 
2ml methanol followed by 2ml H2O. The sample was applied to the column, washed 
with 5ml H2O, followed by 5 ml of Hexane (Fisher scientific, leister, U.K.) and eluted 
with 2ml of methyl formate. Methyl formate was evaporated in speedvac at 4°C, over 
2 hrs, with vacuum. The residue was reconstituted with 0.5ml of Cell-gro (Hyclone, 
USA). Prostaglandins were assayed as specified above (section 2.6.1)  
 
2.9  ADMA EXTRACTION 
ADMA  extraction  with  High-Performance  Liquid  Chromotograpgy  (HPLC)  was 
adapted from Vallance et al. (Vallance et al., 1992). The elusion buffer was made 
with 10% ammonia (NH3), 40% ddH2O and 50% HPLC methanol. 
 
Internal Standard: 
To use L-NMMA as internal standard, 40.3 l of 100mM stock of L-NMMA stock 
(Calbiochem,  Damstadt,  Germany)  was  added  to  59.7 l  of  ddH2O  to  obtain  a 
concentration of 10,000 ng/ l. This was diluted with ddH2O to100 ng/ l and then to 
10 ng/ l L-NMMA stock.  
To  use  homoarginine  as  internal  standard,  1ml  of  ddH2O  was  added  to  1  mg  of 
Homoarginine (MW 224.7, Sigma, U.K.) to obtain a stock solution of 1mg/ml. This 
was then diluted with ddH2O to obtain a 0.1 mg/ml stock. 
 
Standards for the HPLC machine 
36.3 l of 100mM ADMA or SDMA (Calbiochem, Damstadt, Germany) was added to 
63.7 l of ddH2O to obtain a 10 mg/ l concentration stock solution, which was diluted 
to  achieve  100,  10  and  1  ng/ l  concentrations.  Standards  of  ADMA  and  SDMA 
calibrated to give 40, 20, 10, 5 and 1 ng on the column. To obtain 40 ng on column,   53 
40 l of 10 ng/ l of ADMA and 40 l of 10 ng/ l SDMA were added, for 20 ng on 
column, 20 l of 10 ng/ l of ADMA and 20 l of 10 ng/ l SDMA, for 10 ng on column, 
10 l of 10 ng/ l of ADMA and 10 l of 10 ng/ l SDMA, for 5 ng on column, 50 l of 
1 ng/ l of ADMA and 50 l of 1 ng/ l SDMA and for 1 ng on column, 10 l of 1 ng/ l 
of ADMA and 10 l of 1 ng/ l SDMA were added. All solutions were made up to 
100 l by adding the appropriate amount of ddH2O. L-NMMA standard was made by 
adding 20 l (the volume used as internal standard) of 10 ng/ l L-NMMA with 80 l of 
ddH2O to add to 100 l.  
Homoarginine standard was made with 5 l (the volume used as internal standard) of 
0.1mg/ml of homoarginine, with 95 l ddH2O. 
 
HPLC running buffers 
Three buffers were used: Buffer A was made with 935 mls of ddH2O, 50 mls of 1M 
potassium  phosphate  stock  (MW  136,  PH  6.9, Sigma,  U.K.)  and  15  mls  of  1.5% 
acetronitrile  for  HPLC  (VWR,  Leister,  U.K.).  Buffer  B  was  made  with  45% 
acetronitrile, 45% methanol for HPLC (VWR, Leister, U.K.) and 10% ddH2O. Buffer 
C was 5% methanol. 
 
2.9.1  ADMA extraction from plasma 
Plasma was centrifuged at 2000rpm, for 10 minutes, at 4ºC. A volume of 200  l of 
plasma was removed. 20 l of internal standard (10ng/ l) L-NMMA and 780 l of PBS 
was added to the plasma to obtain a total volume of 1ml. Samples were loaded into a 
labelled solid phase extraction (SPE) column (Waters, Oasis®, U.K.). Vacuum pump 
was  turned  on  (Fisher  Scientific,  Leistershire,  U.K.)  and  the  flow  maintained  at 
1ml/min. The flow through was discarded and 1 ml of HCL (100mM) was added to 
the column. Vacuum pump was once again turned on and a flow of 1ml/min was 
obtained. The flow through was discarded and 1ml of methanol (CH3OH) was added 
and flow through discarded as above. Next 1ml of elution buffer was added to the 
column  and  flow  through  was  collected  in  labelled  1.5  ml  Eppendorf  tubes.  The 
sample was placed on a heating block (80 ºC) and the solvent was evaporated to 
dryness under constant flow of nitrogen. The dried extract was redissolved in 100 l of 
ddH2O and mixed well by vortexing. The sample was centrifuged for 2 minutes at 
13000 rpm at 4ºC and 80 l was transferred into a labelled flat bottom insert (Metlab, 
U.K) within a screw-top glass vial. The vial was placed and sample injected into a   54 
HPLC  column  (Agilent,  Cheshire,  U.K.),  consisting  of  a  gradient  pump,  an 
autosampler and a fluorescence detector and the absorbence was monitored. 
 
2.9.2  ADMA extraction from adipose tissue 
Adipose tissue (0.1 g) was ground with a pestle and mortar with liquid nitrogen. It 
was then lysed in protein lysis buffer (1% Triton X-100, Tris-HCL, PH 7.6, 150 mM 
Nacl)  supplemented  with  protease  inhibitors  at  100   M  (Complete,  Boehringer 
Mannhein, U.K.). The Homogenate was centrifuged at 13,000 rpm at 4 ºC, for 15 
minutes and the supranatant were recovered. 100 l of lysate was mixed with 880 l of 
PBS and 20 l of internal standard to make a total of 1ml. The next steps for ADMA 
extraction were as done in plasma samples explained above in 2.9.1. 
 
2.9.3  ADMA extraction from cell culture 
Cell culture samples were centrifuged for 10 min at 2000 rpm at 4ºC. 200 l of the cell 
culture media was removed, 5 l of internal standard (0.1 mg/ml of homoarginine) 
added and the total volume made up to 1ml with 795 l of PBS. The next steps are as 
in described in 2.9.1.  
 
2.10  STATISTICS 
Data were analysed using SPSS version 14 for Windows software (Statistical Package 
for the Social Sciences, SPSS UK Ltd, Chertsey, U.K.). Data in the text are expressed 
as mean (SD) or median (IQR) and in figures as median (IQR) unless otherwise stated. 
Comparisons were carried out by Student’s t-test or Wilcoxon for non parametric data. 
Correlations  were  determined  by  Spearman’s  Rho.  Significance  was  defined  as 
p<0.05.  
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3.1  PATIENT RECRUITMENT 
A total of 31 patients were recruited (25 female/ 6 male). Of the 25 females only 1 
subject was lean (Caucasian), 5 were Afro-Caribbean, 2 were Caucasian with type 2 
diabetes mellitus and 1 was non- diabetic Caucasian on Metformin. Of the 6 males, 3 
were lean (1Afro-Caribbean and 2 Caucasian) and 1 Caucasian with type 2 diabetes 
mellitus.  The  studies  outlined  in  the  following  sections  used  these  patients  to 
investigate  various  parameters  including  depot  specific  release  and  the  effect  of 
systemic insulinaemia. However, the number of patients in each of the studies and the 
characteristics of these sub-sets are set out separately.  
 
3.2  CROSS SECTIONAL STUDY OF ADIPOKINES 
In this section the circulating and depot specific release of five adipokines, namely 
MCP-1, RANTES, adiponectin, IL-6 and leptin, were assessed in a cross-sectional 
study of morbidly obese patients undergoing surgery. The last two adipokines have 
been extensively investigated in the past and were partly used as reference molecules 
here (Madani et al., 2009 (b), in press). However, none of these adipokines have been 
previously assessed in two different abdominal depots, namely omental and gastric fat 
pad. 
 
3.2.1  Circulating adipokines 
Circulating levels of the adipokines were measured. Male, Afro-Caribbean, patients 
who had type 2 diabetes mellitus or were on Metformin and lean patients were 
excluded from the analysis in order to remove the effect of known disease, sex and 
race bias. From three patients no gastric fat pad biopsy was obtained and they were 
also excluded. Therefore out of the possible 31 patients, 14 Caucasian females were 
analysed in this section. Anthropometric and metabolic characteristics of this sub-set 
of patients are shown in table 3.1.  
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Patient’s Parameter  Value 
Female / male  14 / 0 
Age  
(years)  44 (6.5) 
BMI  
(kg/m
2)  46.4 (6.5) 
Body Fat  
(%)  53.4 (7.8) 
Lean Mass  
(%)  47.3 (7.6) 
Diastolic blood pressure  
(mmHg)  84.6 (8.6) 
Total Cholesterol  
(mmol/l)  4.6 (0.9) 
HDL cholesterol  
(mmol/l)  1.2 (0.3) 
LDL cholesterol  
(mmol/l)  3 (0.9) 
Triglyceride  
(mmol/l)  1 (0.3) 
Glucose  
(mmol/l)  5.2 (0.5) 
Insulin  
(MU/l)  7.8 (6.3 – 17.0) 
Adiponectin  
(mg/ml) 
4.9 (2.1– 11.0) 
Leptin  
(ng/ml) 
28.7 (19.1 –38.6) 
RANTES  
(ng/ml) 
57.0 (35.1 – 67.0) 
MCP-1  
(pg/ml) 
220.0 (170.0 – 240.0) 
IL-6  
(pg/ml) 
2.0 (1.0-3.0) 
CRP  
(mg/l)  7.1 (4.9 – 11.2) 
 
Table  3.1:  Anthropometric  and  metabolic  characteristics  of  patients. Data are 
shown as mean (SD) or median (IQR).  
 
Interestingly  all these morbidly obese female individuals, had normal glucose and 
lipid profiles. However in almost two thirds of the patients the normal glucose control 
was achieved by high insulin levels. The systolic blood pressure correlated positively 
with  triglycerides  (r  =  0.65,  p  =  0.02)  and  %  body  fat  (r  =  0.61,  p  =  0.03)  and 
negatively with % lean mass (r = -0.61, p = 0.03). Diastolic blood pressure, similarly,   58 
directly related to % body fat (r = 0.55, p = 0.05) and indirectly with % lean mass (r = 
-0.55, p = 0.05) as well as with total cholesterol (r = -0.62, p = 0.03). Blood pressure 
was  not  associated  with  glucose,  insulin  or  BMI.  Measured  bioimpedence  was 
indirectly related to the systolic (r = -0.55, p = 0.05) and diastolic blood pressure (r = -
0.88, p = 0.000) but directly related to total cholesterol (r = 0.54, p = 0.05) and LDL (r 
= 0.55, p = 0.041).  
In this morbidly obese group, plasma adipokines did not correlate with age, indices of 
obesity, glucose or insulin sensitivity. Total adiponectin was negatively associated 
with both systolic blood pressure (r = -0.62, p = 0.024) and diastolic blood pressure (r 
= - 0.52, p = 0.07). Serum RANTES inversely correlated with HDL-cholesterol (r = -
0.62, p = 0.02), serum IL-6 (r = -0.68, p = 0.008) and serum leptin levels (r = -0.67, p 
= 0.01). CRP did not correlate with indices of obesity, glucose, insulin or any of the 
circulating adipokines.  
 
3.2.2  Depot specific release; Subcutaneous, Omental and Gastric Fat Pad 
Protein array was used as the first tool to analysize the presence of 36 cytokines, 
including RANTES and MCP-1 (figure 3.1).   59 
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Figure 3.1: Protein array of cytokines from subcutaneous, omental and gastric 
fat pad depots. Thirty six cytokines were captured. Out of the possible 36 cytokines, 
13 cytokine were present in the human adipose tissue with densities at least >10% of 
positive  control  (PC).  G-CSF,  CXCL-1,  IL-6,  IL-8,  MCP-1,  MIF,  PAI-1  and 
RANTES had densities ≥50% of the positive control in at least one of the adipose 
tissue  depots  studied.  G-CSF:  Granulocyte  Colony-Stimulating  Factor,  CXCL-1: 
Chemokine (C-X-C motif) Ligand-1, IL-6: Interleukin-6, IL-8: Interleukin-8, MCP-1: 
Monocyte Chemoattractant Protein, MIF: Macrophage migration  Inhibitory  Factor, 
PAI-1:  Plasminogen  Activator  Inhibitor-1,  RANTES:  Regulated  upon  Activation, 
Normal T cell Expressed and Secreted. 
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Out of these 36 cytokines, 13 were present in the human adipose tissue with densities 
at least >10% of positive control and G-CSF, CXCL-1, IL-6, IL-8, MCP-1, MIF, PAI-
1 and RANTES had densities ≥50% of the positive control in at least one of the 
adipose tissue depots studied. G-CSF, CD54 and RANTES showed greater expression 
in the gastric fat pad compared to either the subcutaneous or the omental depots (fig 
3.1). To validate the protein array data using more quantitative techniques, the release 
of some of the adipokines were analysed by ELISA. In contrast to IL-6 and MCP-1, 
RANTES was released in small amounts from the adipose tissue (table 3.2) and its 
systemic levels were relatively high suggesting that adipose tissue is not the main 
source of the release of RANTES. Therefore, although it is clear that RANTES is 
secreted from adipose tissue but it is not certain whether these levels are high enough 
to act as a local chemoattractant.  
 
  Sub- 
cutaneous  Omental  Gastric Fat 
Pad  Plasma 
RANTES  
(ng) 
0.03  
(0.01 – 0.07) 
0.04  
(0.02 – 0.09) 
0.1  
(0.06 - 0.21) 
57.0  
(35.1 – 67.0) 
MCP-1 
(ng) 
6.1 
(2.6 – 9.5) 
6.2  
(2.5 – 13.2) 
6.6  
(3.9 – 8.6) 
0.22  
(0.17 – 0.24) 
Adiponectin 
(ng) 
21.2 
(11.0 – 26.8) 
20.3  
(10.2 –  28.7) 
16.7 
(7.3 – 22.1) 
4929.1 
(2055.8– 10981.2) 
IL-6  
(ng) 
2.3 
(1.0 – 9.9) 
2.4  
(0.5 – 21.5) 
6.2 
(1.0 - 11.7) 
0.002  
(0.001-0.003) 
Leptin  
(ng) 
1.2 
(0.2 - 2.9) 
0.4  
(0.1 - 0.6) 
0.2  
(0.09 - 0.9) 
28.7  
(19.1 –38.6) 
 
Table  3.2:  In  vitro  production  rate  of  adipokines.  Adipokine  production  is 
calculated as ng per gm of adipose tissue per hour in organ culture baths and ng per 
ml in circulating levels. Data shown in Median +/- IOR (n = 14).  
 
 
RANTES was released in significantly higher amounts, per gm of tissue, from the 
gastric fat pad compared to the omental (p = 0.03) or subcutaneous (p = 0.01) depots 
(figure  3.2).  Subcutaneous  leptin  release  was  significantly  higher  compared  to 
omental depot (p = 0.05), but there was no difference between either of these depots 
and  the  gastric  fat  pad  release.  There  was  a  trend  towards  higher  subcutaneous 
adiponectin release compared to that from the gastric fat pad (p = 0.08) but did not   61 
reach  significance.  Neither  MCP-1,  nor  IL-6  release  were  significantly  different 
between the depots. Comparisons were made using Wilcoxon rank test.   62 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Depot specific RANTES release. RANTES was released in significantly 
higher amount from the Gastric Fat Pad (GFP) compared to subcutaneous (p = 0.01) 
or omental (p = 0.03) depots. Comparisons were made by Wilcoxon rank test.  
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p = 0.03 
p = 0.01   63 
 
3.2.3  Chemokine interactions 
Subcutaneous RANTES release correlated significantly with that from omental tissue 
(r  =  0.54,  p  =  0.05).  The  release  of  RANTES  from  both  these  depots  correlated 
significantly with omental MCP-1 (for subcutaneous RANTES r = 0.66, p = 0.02; for 
omental RANTES r = 0.80, p = 0.001) and omental IL-6 (for subcutaneous RANTES 
r = 0.62, p = 0.02; for omental RANTES r = 0.55, p = 0.04). There were no significant 
correlations between the release of RANTES from the gastric fat pad and the other 
adipokines. Furthermore, subcutaneous MCP-1 release correlated with gastric fat pad 
MCP-1 (r=0.74, p=0.01) and omental MCP-1 with omental IL-6 (r = 0.65, p = 0.02). 
There were no associations between the release of any of the adipokines from the 
organ bath and serum CRP.  
 
In  the  next  two  sections,  the  study  focused  on  two  pathways  that  may  mediate 
adipokine secretion and function, namely the COX and NOS pathways. In section 3.2, 
the  in  vitro  inhibition  of  the  components  of  the  COX  pathway  was  investigated; 
namely  the  activity  of  PGE2S  and  PGI2S  and  the  secretion  of  the  related 
prostaglandins. In section 3.3 the generation of ADMA and the expression DDAH, as 
components of the NOS pathway, as well as the release of adiponectin and the effect 
of insulin, were assessed. 
 
 
 
 
 
 
 
 
   64 
 
3.3  IL-6 AND COX PATHWAY 
In this section the effect of in vitro inhibition of the COX pathway, with non-selective 
and  selective  COX  inhibitors,  on  the  release  of  IL-6  from  different  depots  was 
assessed in a subgroup of patients. Activities of PGI2S and PGE2S were measured as 
well  as  the  protein  expression  in  both  subcutaneous  and  omental  depots.  The 
expression was then compared between the adipocytes and the stoma vascular fraction 
of the adipose tissue. 
In this group of morbidly obese female (patient characteristics shown in table 3.1) no 
significant difference was seen between the subcutaneous and omental IL-6 release 
(figure 3.3).   65 
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Figure 3.3: Depot specific differences in IL-6 release in human white adipose 
tissue. No significant difference between the two depots (n=14). Graph shown as box 
plot and data as median ± IQR. Comparisons were made by Wilcoxon Rank test.   66 
The effect of Aspirin at low dose (0.2 mM) and high dose (5 mM) as well as NS-398 
(COX-2  selective  inhibitor)  and  SC-560  (COX-1  selective  inhibitor)  at  low  dose 
(0.01 M) and high dose (1 M) on IL-6 release in human organ culture was assessed 
in a subgroup of patients. IL-6 release from the subcutaneous depot was significantly 
reduced by low dose aspirin but not by high-dose aspirin (n=5, p = 0.043, figure 3.4). 
This effect was not seen in the omental depot. Subcutaneous IL-6 release was reduced 
by  low  (p  =  0.08)  and  higher  dose  (p  =  0.07)  NS-398,  but,  they  did  not  reach 
significance. No effect was seen in the omental depot. SC-560, contrary to that in 
mouse adipose tissue had no significant effect on IL-6 release from subcutaneous or 
omental depots at either dose (data not shown).    67 
 
 
 
 
 
Figure 3.4: The effect of in vitro COX inhibition on IL-6 release from human 
subcutaneous  and  omental  white  adipose  tissue.  Aspirin,  a  non-selective  COX 
inhibitor, significantly reduced subcutaneous IL-6 release at the low dose only (p = 
0.04). This was not seen in the omental depot. Graph shown as box plot and data as 
median ± IQR (n = 5). Comparisons were made by Wilcoxon Rank test. 
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Activities of PGI2S and PGE2S were measured as 6-keto PGF1α (stable prostacyclin 
metabolite) and PGE2 release respectively and expressed in ng of the prostaglandin 
released  per  gm  of  adipose  tissue  per  hour.  There  was  no  significant  correlation 
between IL-6 release and PGE2S or PGI2S activity in either subcutaneous (PGE2S: r = 
- 0.205, p = 0.74; PGI2S: r = 0.316, p = 0.541) or omental (PGE2S: r = 0.316, p = 
0.684;  PGI2S  r  =  0.632,  p  =  0.368)  depot.  However  there  was  significant  direct 
correlation between subcutaneous PGI2S and omental PGE2S activity (r = 0.949, p = 
0.014). PGI2S activity was found to be higher in the omental depots (figure 3.5) but 
Aspirin, COX-1 or COX-2 had no effect on PGI2S or PGE2S activity. All correlations 
were performed by Spearman’s Rho.   69 
 
 
 
 
 
 
Figure 3.5: Comparison of subcutaneous and omental PGE2S and PGI2S activity. 
6-keto PGF1α (PGI2S activity) is lower in subcutaneous compared to omental depots 
(p = 0.043). No difference is seen in the IL-6 or PGE2 release between depots. Graph 
shown as box plot and data as median ± IQR (n = 5). Comparisons were made by 
Wilcoxon. 
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In a subgroup of patients, the stromavascular fraction was separated from adipose 
tissue and PGI2S protein expression was investigated by Western blot analysis. There 
was higher PGI2S expression in the stromavascular fraction of the omental depots 
compared to the subcutaneous stromavascular fraction (figure 3.6).  
 
Figure 3.6: Western blot analysis for PGI2 synthase in: (a) human adipose tissue 
(b) the enriched the stromavascular fraction (SVF). The depot specific difference 
in PGI2S expression is apparent in the SVF but not in the intact adipose  
tissue.  Conditions:  Primary  antibody  anti-human  PGI2  synthase;  1:1000  dilution 
overnight  at  4
oC.  Secondary  ant-rabbit  IgG-horseradish  peroxidase  conjugated 
antibody at 1:3000 dilution for 2 h at room temperature. Film exposed for 10 minutes. 
Molecular weight of PGI2S is 57 KDa. 
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3.4  ADMA, DDAH, ADIPONECTIN AND THE EFFECT OF INSULIN 
Although all patients in this study group were normoglycaemic, this was achieved by 
high insulin levels in some patients. Therefore the aim of this study was to investigate 
the effect of insulin by assessing the differences in the expression of DDAH, ADMA 
and  release  of  adiponectin  between  the  normoinsulinaemic  and  hyperinsulinaemic 
groups, as well as comparing the subcutaneous and omental depots.  
In this section of the possible 31 patients 17 were analysed. In order to exclude the 
effect of sex and race; 5 Afro-Caribbean female, 6 male, 2 patient with type 2 diabetes 
and 1 obese patient on Metformin, were excluded. Details of the patients are in table 
3.3. 
Patient's Parameter  Value 
Female / Male  17 / 0 
Age  
(years)  43.44 (7.87) 
BMI  
(kg/m
2)  43.83 (10.14) 
Body fat  
(%)  52.57 (7.05) 
Lean mass  
(%)  48.3 (7.7) 
Insulin  
(MU/l)  7.75 (7.13 – 15.03) 
Total Cholestrol  
(mmol/l)  4.55 (3.85-4.88) 
HDL cholesterol  
(mmol/l)  1.2 (1.0 – 1.4) 
LDL cholesterol  
(mmol/l)  2.95 (2.3 – 3.28) 
TG cholesterol  
(mmol/l)  1.1 (1.0 – 1.2) 
CRP  
(mg/l)  7.1 (4.9 – 11.2) 
 
Table  3.3:  Anthropometric  and  metabolic  characteristics  of  patients. Data are 
shown in mean +/- SD or median +/-IQR.  
 
Systolic  blood  pressure  positively  correlated  with  BMI  (p  =  0.05,  r  =  0.48)  and 
glucose  (r  =  0.47,  p  =  0.05).  Diastolic  blood  pressure,  although  not  statistically 
significant,  was  closely  related  to  BMI  (r  =  0.43,  p  =  0.08).  Bioimpedence  was 
associated with total cholesterol (r = 0.5, p = 0.04), LDL (r = 0.53, p = 0.03) and 
percentage lean mass (r = 0.5, p = 0.04) but negatively associated with BMI (r = -0.71,   72 
p = 0.001), percentage body fat (r = -0.5, p =0.04) and diastolic blood pressure (r = -
0.6, p = 0.02). Systemic CRP levels did not correlate with insulin, glucose, blood 
pressure or any indices of obesity.  
 
3.4.1  ADMA 
Plasma ADMA and SDMA were analysed and ADMA/SDMA ratio was calculated.  
Serum ADMA correlated with serum SDMA (r = 0.79, p= 0.000). Circulating ADMA 
correlated  negatively  with  triglyceride  (r  =  -0.53,  p=  0.03)  and  there  was  no 
association  with  BMI  or  glucose.  However  there  was  a  trend  towards  positive 
correlation  between  circulating  ADMA  and  insulin  (r  =  0.45,  p  =  0.061). 
ADMA/SDMA ratio was directly associated with systolic blood pressure (r = 0.53, p 
= 0.03) and although closely related, it did not reach statistical significance with the 
diastolic blood pressure (r = 0.46, p = 0.07). 
ADMA  extracted  from  subcutaneous  and  omental  explants  were  successful  in  13 
patient.  Explant  ADMA  release  was  significantly  higher  from  the  omental  depot 
compared to the subcutaneous (figure 3.7). Explant SDMA extraction was completed 
in 9 patients. Tissue ADMA and SDMA was only successfully extracted from adipose 
tissue  of  six  patients  and  no  significant  differences  were  found  between  depots. 
Insulin also positively correlated with subcutaneous tissue ADMA (r = 0.83, p = 0.04) 
and  subcutaneous  tissue  SDMA  (r  =  0.70,  p  =  0.03)  and  nearly  associated  with 
omental tissue ADMA (r = 0.7, p = 0.08) and omental tissue SDMA (r = 0.7, p = 
0.08). However insulin negatively correlated with subcutaneous explant SDMA (r = -
0.89, p = 0.02). BMI was positively (r = 0.57, p = 0.45) and percentage lean mass was 
negatively (r = -0.56, p = 0.05) associated with omental explant ADMA. Systolic 
blood pressure indirectly related to omental tissue SDMA (r = -0.83, p = 0.02) and 
there  was  a  close  indirect,  but  not  statistically  significant,  association  with 
subcutaneous tissue ADMA (r = -0.78, p = 0.07). HDL correlated negatively with 
subcutaneous explant ADMA (r = -0.56, p = 0.05) and positively with subcutaneous 
explant SDMA (r = 0.85, p = 0.04) depots. Triglyceride negatively correlated with 
omental tissue SDMA (r = -0.74, p = 0.06). Subcutaneous tissue SDMA correlated 
negatively with cholesterol (r = 0.78, p = 0.04) and LDL (r = 0.78, p = 0.04). CRP 
was  strongly  related  to  subcutaneous  tissue  ADMA  (r  =  0.9,  p  =  0.03).  All 
correlations were by Spearman’s Rho.    73 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.7:  ADMA  extraction  from  explants.  Omental  ADMA  levels  were 
significantly higher than those from the subcutaneous depot (p = 0.025). Explants 
were set up as 0.2gm of adipose tissue in 1 ml of organ culture for 24 hrs. Graph 
shown as box plot and data as median ± IQR (n = 13, 4 missing data). Comparisons 
were made by Wilcoxon Rank test. 
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3.4.2  DDAH expression 
DDAH1 and DDAH2 primers were tested with dilution series (figure 3.8). GAPDH 
or/and β-actin were used as control.  
 
 
 
 
 
Figure 3.8: Dilution series. a) Dilution series of DDAH2 b) Dilution series of β-actin. 
Dilutions used were: neat, one in two, one in four and one in eight. Samples were 
done in triplicate. Each colour represents one series of dilution.  
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Figure 3.9: Amplification plot of DDAH1. Taq-man® rt-PCR amplification plot of 
DDAH1. Samples were tested in triplicates. Amplification plot shows a close overlap 
of the ct values of the triplicates. 
   76 
 
Omental DDAH1 expression was directly related to percentage lean mass (r = 0.54, p 
= 0.04). There was no correlation between DDAH1 or DDAH2 expression and BMI, 
blood pressure, serum glucose, insulin, lipids or CRP.  
Not surprisingly there was a direct correlation between subcutaneous and omental; 
∆ct  DDAH1  (r  =  0.69,  p  =  0.004)  and  this  nearly  reached  significance  with 
subcutaneous ∆ct DDAH2 (r = 0.48, p = 0.06). There was no difference in expression 
of DDAH1 or DDAH2 between subcutaneous and omental depots (figure 3.10).   ct 
values were used as explained in section 2.2.4.  
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Figure 3.10: Comparison between subcutaneous and omental DDAH1and 2. No 
difference found between subcutaneous (Sc) and omental (Om) DDAH1 & DDAH2 
expression. Formula explained in section 2.2.4(n =15, 2 missing) 
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DDAH  2  was  expressed  in  higher  amount  compared  to  DDAH  1  in  both  depots 
(figure 3.11). 
 
 
 
 
 
Figure 3.11: Comparison of DDAH1 and DDAH2 in subcutaneous and omental 
depots. There were significantly higher levels of DDAH2 compared to DDAH1 in 
both omental (p = 0.008) and subcutaneous (p = 0.039) depots. Graph shown as box 
plot and data were median +/- IQR (n = 15). Comparisons were made by Wilcoxon. 
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There were no significant differences in the expression of DDAH1 or DDAH2 from 
the stromavascular fraction between depots either. There was higher expression of 
DDAH2 compared to DDAH1 in the stromavascular fraction of both subcutaneous (p 
= 0.0046) and omental (p = 0.018) depots but not in the whole, unfractionated adipose 
tissue of each depots (figure 3.12). 
 
 
 
 
 
Figure 3.12: Comparison of DDAH1 and DDAH2 expression between adipose 
tissue and stromavascular fraction of subcutaneous and omental depots.  
No depot specific differences were seen of DDAH1 or DDAH2 in adipose tissue or 
the stromavascular fraction. There was higher expression of DDAH2 compared to 
DDAH1  in  the  stromavascular  fraction  of  both  subcutaneous  (p  =  0.0046)  and 
omental (p = 0.018) depots but neither in subcutaneous adipose tissue (p = 0.859), nor 
in omental adipose tissue (p = 0.086). Graph shown as box plot of   ct values and 
data as median +/- IQR (n = 9). Comparisons were made by Wilcoxon.  
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3.4.3  Adiponectin 
In chapter 3.1.1 no correlations were found between any of the adipokines, including 
serum  immunoreactive  adiponectin,  and  insulin  or  the  indices  of  obesity,  perhaps 
because this is a morbidly obese population. As adiponectin may circulate in different 
multimeric  structures,  serum  samples  were  re-analysed  measuring  the  total 
adiponectin,  as  well  as  the  levels  of  high  molecular  weight  (HMW),  medium 
molecular  weight  (MMW),  low  molecular  weight  (LMW)  and  HMW+MMW 
isoforms.  
There  was  a  trend  towards  a  negative  correlation  between  insulin  and  total 
adiponectin (r = -0.47, p = 0.06), MMW (r = -0.42, p = 0.092) and LMW (r = -0.47, 
p= 0.07). BMI also was negatively associated with total adiponectin (r = -0.52, p = 
0.05), HMW (r = -0.52, p = 0.031), LMW (r = - 0.57, p = 0.016) and MMW+HMW (r 
=  -0.48,  p  =  0.05).  Serum  total  adiponectin  was  positively  associated  with  HDL-
cholesterol (r = 0.61, p = 0.01), HMW (r = 0.58, p = 0.02), MMW (r = 0.61, p = 0.02), 
HMWMMW (r = 0.6, p = 0.01), but not with LMW.  
Both  systolic  and  diastolic  blood  pressures  were  negatively  associated  with  total 
serum adiponectin (r = -0.53, p = 0.03; r = -0.60, p = 0.02), HMW (r = -0.67, p = 
0.005;  r  =  -0.62,  p  =  0.008),  MMW  (r  =  -0.50,  p  =  0.05;  r  =  -0.48,  p  =  0.05), 
MMWHMW (r = -0.63, p = 0.001; r = -0.61, p = 0.01). There was no correlation 
between circulating adiponectin and CRP.  
Adiponectin release in explants did not correlate with BMI, glucose or insulin levels. 
However  subcutaneous  explant  adiponectin  showed  a  positive  trend  with  total 
adiponectin (r = 0.44, p = 0.09) and with HMW (r = 0.45, p = 0.07). Subcutaneous 
and omental explant adiponectin were also closely related (r = 0.56, p = 0.02).  
 
Correlation between ADMA, DDAH and adiponectin 
Although  neither  the  serum  ADMA,  nor  SDMA  correlated  with  circulating 
adiponectin  levels,  the  ADMA/SDMA  ratio  was  negatively  associated  with  total 
adiponectin (r = -0.51, p = 0.04), HMW (r = -0.54, p = 0.03), LMW (r = - 0.60, p = 
0.01), MMW+HMW (r = -0.50, p = 0.04) and MMW (r = - 0.44, p = 0.08). There 
were no significant associations between serum ADMA/SDMA or explant ADMA 
release and adiponectin explant secretion from either depot.   81 
Depot ADMA release was not related to serum adiponectin levels but there was a 
significant positive correlation between subcutaneous SDMA and total adiponectin (r 
= 0.94, p = 0.005), HMW (r = 0.94, p = 0.005and MMWHMW (r = 0.94, p = 0.005). 
Subcutaneous ∆ct DDAH2 correlated negatively with serum ADMA (r = -0.50, p = 
0.05) and serum SDMA (r = - 0.73, p = 0.001).  
Subcutaneous ∆ct DDAH1 correlated with subcutaneous adiponectin levels (r = 0.70, 
p = 0.002), and with subcutaneous ∆ct DDAH2 (r = 0.49, p = 0.057) and omental ∆ct 
DDAH1 (r = 0.69, p = 0.004). Omental ∆ct DDAH1 and omental ∆ct DDAH2 were 
also closely related (r = 0.55, p = 0.035). ∆ct DDAH1 and ∆ct DDAH2 from neither 
depot  was  related  to  serum  adiponectin  levels.  All  correlations  were  made  by 
Spearman’s Rho.  
 
3.4.4  Effect of insulinaemia on ADMA, DDAH and adiponectin 
Patients were divided into two groups depending on their fasting systemic insulin 
levels  and  data  were  compared  (table  3.4).  Circulating  total  adiponectin,  HMW, 
MMW and HMWMMW levels were all significantly higher in the normoinsulinaemic 
group but depot specific release of adiponectin was not different between the two 
groups. 
Both the adipose tissue content and release of ADMA and SDMA were only available 
in 1 normoinsulinaemic patient and therefore analysis was not possible. Other data 
were  available  in  2  of  normoinsulinaemic  obese  patients  and  therefore  all 
comparisons below should be considered rather preliminary. All comparisons were 
made by independent t-test. Serum ADMA was lower in the normoinsulinaemic group 
(p  =  0.046);  mean  [1.9(0.1)  vs  1.7(0.55)  µM/l}.  There  were  no  differences  in 
subcutaneous and omental DDAH 1 and DDAH 2 expression between the groups.    82 
 
 
 
 
Normoinsulin- 
aemia 
Hyperinsulin- 
aemia  P value 
Number  4  13   
Age  
(years)  43.75 (4.35)  42.9 (8.65)  NS (0.9) 
Sex  All Female  All Female   
Body fat  
(%)  52.78 (10.64)  51.37 (5.4)  NS (0.8) 
BMI  
(kg/m
2)  43.2 (16.1)  42.5 (9.7)  NS (0.9) 
Glucose  
(mmol/l)  4.6 (4.45 – 4.78)  5.3 (4.9 – 5.8)  0.009 
Insulin  
(MU/l)  5.11 (4.4 – 5.43)  9.8 (7.6 – 17)  0.023 
Total Adiponectin  
(µg/ml)  7.0 (2.1 – 11.1)  3.21 (2.3 – 4.5)  0.031 
HMW-Ad  
(µg/ml)  3.3 (0.7 – 6.1)  1.1 (0.69 – 1.96)  0.03 
MMW-Ad  
(µg/ml)  1.43 (0.48 – 2.5)  0.83 (0.6 – 1.14)  0.03 
LMW-Ad  
(µg/ml)  1.97 (0.9 –2.28)  1.01 (0.75 – 1.64)  NS (0.12) 
HMW+MMW-Ad  
(µg/ml)  5.05 (1.2 – 8.8)  2.02 (1.3 – 2.96)  0.03 
Sc Adiponectin 
(ng/ml/hr) 
31.97  
(13.66 – 49.45)  21.1 (11.2 – 29.8)  NS (0.12) 
Om Adiponectin 
(ng/ml/hr) 
23.1  
(11.82 – 101.56)  19.4 (10.2 – 28.51)  NS (0.89) 
 
 
Table  3.4:  Comparison  of  the  circulating  and  tissue  release  of  adiponectin  in 
normoinsulinaemic and hyperinsulinaemic individuals. Insulin levels > 7.0 MU/l 
were recorded as hyperinsulinaemia. Data are shown in mean (SD) of median (IQR). 
Comparisons  were  made  by  independent  T  Test,  equal  variance  assumed.  HMW: 
High Molecular Weight, LMW: Low Molecular Weight, MMW: Medium Molecular 
weight.  
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Serum ADMA and adiponectin levels were analysed in 25 patients, including male, 
lean  and  diabetic  patients  but  excluding  the  6 Afro-Caribbean  individuals.  As  the 
numbers were small adequate comparisons could not be made. However patients were 
divided into the five groups shown in figure 3.13 to assess any interesting trends that 
may later be followed up in greater number of patients. Serum ADMA levels seemed 
comparable  and  elevated  in  the  obese  individual,  whether  normoinsulinaemic  or 
hyperinsulinaemic, compared to lean individuals. Circulating ADMA was also lower 
in  the  obese  normoinsulinaemic  and  hyperinsulinaemic  subjects  on  Metformin 
compared to obese subjects not on Metformin (figure 3.13). 
 
Plasma adiponectin was, as expected, higher in the lean compared to the obese hyper-
insulinaemic  patients.  Patients  on  Metformin  had  elevated  plasma  adiponectin 
compared to their counterparts not on Metformin (figure 3.14).   84 
 
 
 
 
 
 
 
Figure 3.13: Comparison of serum ADMA in lean, normoinsulinaemic obese and 
hyperinsulinaemic  obese  and  diabetic  on  Metformin  and  obese 
normoinsulinaemic on Metformin. Although comparison test were not performed, 
because of small number and sex miss match, but serum ADMA in lean and diabetic 
patients on Metformin seems to be lower. The obese normoinsulinaemic patient on 
Metformin had a lower serum ADMA compared to patients not on Metformin. Graph 
shown as box plot and data as median +/- IQR. Obese normoinsulinaemic n=2 (All 
female), Obese hyperinsulinaemic n=16 (14F/2M), Lean n=3 (1F/2M), Diabetics on 
Metformin (n=3, 2F/1M), Obese normoinsulinaemic on Metformin (n=1, F).  
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Figure 3.14: Comparison of serum adiponectin in lean, normoinsulinaemic obese 
and hyperinsulinaemic obese and diabetic individuals. Although comparison test 
were not performed, because of small number and sex miss match. However, serum 
adiponectin in diabetic patients on Metformin seems to be higher compared to obese 
hyperinsulinaemic  patients  not  on  Metformin.  This  may  be  the  case  for  obese 
normoinsulinaemic  on  Metformin  as  well  compared  to  the  same  group  not  on 
Metformin.  Graph  shown  as  box  plot  and  data  as  median  +/-  IQR.  Obese 
normoinsulinaemic n=2 (All female), Obese hyperinsulinaemic n=16 (14F/2M), Lean 
n=3 (1F/2M), Diabetics on Metformin (n=3, 2F/1M), Obese normoinsulinaemic on 
Metformin (n=1, F). 
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CHAPTER 4: DISCUSSION   87 
 
4.1  ADIPOKINES  
Several  proinflammatory  cytokines  and  chemokines,  including  RANTES,  MCP-1, 
adiponectin, leptin and IL-6, were released in vitro from the subcutaneous abdominal 
and two visceral depots studied: the omental fat and the gastric fat pad. However, 
there were significant differences only in RANTES secretion between the different 
adipose tissue depots studied in this population of morbidly obese patients undergoing 
surgery. These subjects secreted significantly greater amounts of RANTES from their 
gastric fat pad than from adipose tissue of abdominal subcutaneous or omental origin. 
Wu  et  al.  reported  higher  expression  of  RANTES
  in  visceral  compared  with 
subcutaneous adipose tissue of morbidly obese
 humans (Wu et al., 2007). However, 
this  study  is  the  first  to  compare  two  visceral  depots,  the  gastric  fat  pad  and  the 
omental. Previous studies have assumed all visceral depots were similar.  
The gastric fat pad lies in close anatomical proximity to the stomach, sitting in the 
angle  of  His.  This  depot  is  highly  vascularised  and  may  become  thickened  in 
morbidly obese subjects and it is thought that its resection may prevent obstruction 
after gastric banding (Ren & Fielding, 2003; Sacks et al. 2007). The increased release 
of RANTES from the gastric fat pad may be due to local regulation by gastrointestinal 
factors. The close association between omental and subcutaneous RANTES, but not 
with that from the gastric fat pad, may also imply that this depot is independently 
regulated. These differences in RANTES secretion between visceral adipose tissue 
depots could be explained by possible variations in the proportions of the components 
that make up each tissue depot, with particular respect to the stromavascular fraction, 
which accounts for the majority of chemokine and cytokine release (Clement et al., 
2004). It could be that different depots are more susceptible to the inflammatory cell 
infiltration seen in obesity or conversely that some have a greater tendency for the 
adipocyte fraction to undergo greater hypertrophy, therefore causing greater release of 
chemokines, depending on which cell is responsible for their secretion. This would 
further enhance our understanding of the ‘apple and pear’ affect of obesity and may 
provide some evidence to suggest that the increased risk of co-morbidity associated 
with visceral fat may be refined to the type of visceral depot involved. It has been 
reported that IL-6 and MCP-1 are predominantly secreted by the stromavascular cells 
(Trujillo & Scherer, 2006) and it is likely that the same could apply for RANTES, 
since it is has long been recognized as being a product of immune cells. Although   88 
adipose tissue is known to express a constantly increasing number of chemokines and 
cytokines;  however,  not  all  of  these  are  actively  secreted  into  the  circulation 
(Mohamed-Ali et al. 1997 (a)). Systemic levels of RANTES were approximately 100-
fold higher than those being released from any of the adipose tissue depots studied. 
Therefore,  it  would  be  reasonable  to  suggest  that  while  adipose  tissue  is  able  to 
produce this chemokine, its contribution to systemic levels may be less significant. 
Other cells or tissues within the body, such as T-cells and other immune cells, are 
likely to be more potent producers of RANTES, thereby contributing significantly to 
circulating levels. This was further confirmed by a lack of association between its 
circulating  levels  and  indices  of  obesity.  In  contrast,  IL-6  production  from  the 
subcutaneous  (Mohamed-Ali  et  al.  1997  (a)),  as  well  as  from  the  visceral  depot 
(Fontana et al., 2007), contributes significantly to the systemic circulation, with the 
potential to have endocrine effects on various organs, especially in obesity. We have 
also  shown  the  in  vitro  release  of  RANTES  from  the  epicardial  and  thoracic 
subcutaneous  adipose  tissue  depots  in  individuals  undergoing  cardiac  surgery  for 
valve replacement and without coronary artery disease (Madani et al. 2009 (a), in 
press). In this group the RANTES release from epicardial adipose tissue, but not the 
thoracic  subcutaneous,  correlates  positively  with  BMI  and  is  enhanced  in  obese 
individuals.  So  while  epicardial  RANTES  is  related  to  obesity,  neither  systemic 
RANTES nor its release from the subcutaneous and the abdominal visceral adipose 
tissues are good markers of adiposity. The significant heterogeneity in the release of 
RANTES  from  the  various  depots  suggests  differential  regulation  by 
autocrine/paracrine  factors.  Given  that  in  other  cell  populations  RANTES  affects 
intracellular pathways that are central to adipocyte biology (Zhang et al. 2002), it 
would be interesting in the future to evaluate adipose tissue as a target, rather than as 
a source, of RANTES. 
 
The two pathways involved in mediation of the secretion of these adipokines namely; 
COX and NOS, were then investigated further and discussed in the following sections. 
 
4.2  COX PATHWAY 
In  this  morbidly  obese,  female  group  of  patients  there  were  no  depot  specific 
differences in the release of IL-6. The in vitro pharmacological inhibition of COX 
with  low  dose  aspirin,  a  non-selective  COX  inhibitor,  significantly  reduced   89 
subcutaneous IL-6 release, but this was not apparent at higher doses or in the omental 
depots. COX-1 selective inhibitors had no effect on IL-6 release from either depot. 
However  there  was  a  trend  towards  reduced  IL-6  release  by  COX-2  selective 
inhibitors  in  subcutaneous  but  not  the  omental  depots.  Experiments  performed  on 
mice in our group (Ogston et al., 2008) found that the treatment of murine adipose 
tissue in organ cultures with aspirin resulted in a significant reduction of IL-6 release 
which was dose dependent in both subcutaneous and gonadal depots. COX-2 selective 
inhibitor also brought about a significant reduction in IL-6 release from both depots 
but this did not appear to be dose-dependent, with the maximal effect observed at the 
lower  dose.  This  difference  between  human  and  murine  results  may  be  due  to 
problems with storage of the inhibitors used, as the experiments with the human tissue 
were carried out a few years after the murine experiments but using aliquots of the 
same inhibitors. The relatively small number of patients used in this study (n=5) could 
have influenced results as well. Therefore these results need to be confirmed both 
using new reagents and in a larger cohort.  
Endogenous PGI2S and PGE2 secretions were unrelated to IL-6 secretion in human 
tissue; however this was not the case in mice (Ogston et al., 2008). Experiments in 
mice  revealed  greater  PGI2S  protein  and  activity  in  gonadal  compared  to 
subcutaneous  adipose  tissue.  In  human  tissue  PGI2S  activity,  but  not  its  protein 
expression, was found to be higher in the omental depots. However, in a subgroup of 
patients,  in  whom  fractionated  adipose  tissue  was  available  the  omental 
stromavascular  fraction  showed  higher  PGI2S  expression  compared  to  that  of  the 
subcutaneous depot. No depot specific differences were apparent for PGE2S activity. 
The effect of ingested aspirin on the adipose tissue in mice using ultra-low doses was 
investigated (Cyrus et al., 2002). Low dose aspirin significantly reduced circulating 
IL-6 in vivo in mice. Specific inhibition of COX-2 in vitro also reduced adipose IL-6 
and abolished the differences seen between subcutaneous and gonadal adipose tissue 
in mice. Even at these doses aspirin inhibited the release of 6-keto-PGF1α  and IL-6, 
though not PGE2, from murine white adipose tissue. Given that both COX isoforms 
are constitutively expressed, it seems that in this tissue, as in endothelial and smooth 
muscle cells (Schildknecht et al., 2004), PGI2 synthesis is more coupled to COX-2 
activity  and  drives  the  IL-6  secretion.  Furthermore,  depot-specific  differences  in 
expression and activity of PGI2S may explain the greater release of IL-6 from omental 
adipose tissue.    90 
Dietary and pharmacological interventions that lower the activity of COX mediated 
PGI2S  in  adipose  tissue  are  therefore  likely  to  lead  to  local  inhibition  of  IL-6 
production. The novel observations of the susceptibility of the adipose tissue COX/PG 
pathway to ASA inhibition, as well as the fat depot-specific expression of PGI2S and 
production of PGI2 has important implications not only for the control of IL-6 release, 
but perhaps also for other important PGI2 regulated functions in adipose tissue, such 
as adipogenesis (Ailhaud, 1999) and local adipose tissue blood flow. The relevance of 
this pathway needs further clarification in human adipose tissue. 
 
4.3  NOS PATHWAY 
Serum ADMA, an endogenous NO inhibitor, levels have been shown to be elevated in 
several  clinical  syndromes  associated  with  insulin  resistance  and  increased 
cardiovascular disease risk (Vallance 2001; Kielstein et al., 1999; Zavaroni et al., 
1999),  including  obesity  (Eid  et  al.  2004).  In  this  study  ADMA  levels  were 
determined in the serum, organ culture of adipose tissue and whole adipose tissue, of 
both subcutaneous and omental depots, in morbidly obese females. Serum ADMA 
was positively associated with insulin but not with glucose and the ADMA/SDMA 
ratio  was  proportional  to  systolic  blood  pressure,  perhaps  suggesting  endothelial 
dysfunction. 
Hypercholesterolemia  is  thought  to  directly  reduce  DDAH  activity  resulting  in 
ADMA  accumulation  (Chan  &  Chan,  2002).  However,  in  contrast  to  published 
literature (Stuhlinger et al., 2002), there was a negative correlation between serum 
ADMA and triglyceride. The median serum ADMA in this morbidly obese group was 
1.84 mM/l (1.03 – 2.06). Schulze et al. analyzed 500 healthy subjects, aged 19 to 75 
years, with the aim of determining a reference value for ADMA and reported a mean 
concentration of 0.69 mol/l (± 0.2). In the Athero Gene Study on 1758 patients with 
subclinical  coronary  artery  disease  but  without  a  recurrent  cardiovascular  event 
reported a median serum ADMA value of 0.63 mol/l (Schnabel et al., 2005). In the 
present  study,  although  statistical  comparison  could  not  be  made  accurately, 
circulating ADMA seemed lower in the lean individuals at 0.75 mM/l (0.65 – 0.8). 
This is in keeping with report by Kryzanowska et al., showing elevated ADMA levels 
in morbidly obese subjects compared to normal weight individuals, and a significant 
reduction in systemic ADMA, along with improvement in several components of the 
metabolic syndrome, following gastroplasty (Kryzanowska et al., 2004).    91 
No  depot  specific  differences  in  tissue  ADMA  was  demonstrated  here.  However 
ADMA extraction from explants in thirteen obese patients showed higher levels being 
generated  from  the  omental  compared  to  the  subcutaneous  depot.  The  direct 
associations of omental ADMA release and BMI suggests a link between visceral 
obesity  and  endothelial  dysfunction.  Higher  omental  ADMA  levels  could  reflect 
lower activity or expression of the catalysing enzymes, DDAH, or higher synthetic 
enzymes, PRMTs, in this depot. Published results have confirmed the expression of 
the  whole  gene  set  that  codes  for  the  enzymatic  system  responsible  for  the 
biosynthesis  and  degradation  of  ADMA  in  the  human  adipose  tissue;  PRMT1-6, 
DDAH1 and 2 and all forms of NOS (Spoto et al., 2007). This is the only published 
study  comparing  subcutaneous  and  omental  ADMA  release,  although  tissue  was 
obtained only from two healthy patients. Authors reported higher DDAH2 in visceral 
adipose tissue and higher DDAH1 in the subcutaneous depot (Spoto et al., 2007). In 
our study, although DDAH2 was expressed in higher amounts compared to DDAH1 
in both depots but there was no depot specific difference for DDAH1 or DDAH2. In 
order  to  assess  whether  the  expression  of  DDAH  reflects  the  stromavascular 
components of this tissue, in a subgroup of patients the stromavascular fraction was 
separated from adipose tissue. DDAH expression from adipocytes was not obtained 
due to poor RNA yields but DDAH2 was found to be higher compared to DDAH1, in 
the stromavascular fraction of both depots and once again no difference was seen 
between depots. We did not compare the expression of PRMTs between depots in this 
study but this would be interesting to evaluate in the future. Spoto et al. reported over 
expression  of  PRMT6  in  the  visceral  adipose  tissue  but  higher  PRMT1-4  in  the 
subcutaneous  depot.  Experiments  on  mice  in  our  group  found  higher  PRMT3 
expression  in  gonadal  adipose  tissue  compared  to  the  subcutaneous  depot 
(unpublished results).  
Insulin-induced vasorelaxation in both humans and animals has been attributed to its 
ability  to  stimulate  endothelium-dependent  NO  generation  (Scherrer  et  al.,  1994; 
Bertuglia et al., 1998). Reduced sensitivity to the metabolic actions of insulin and 
impaired  NO  mediated  vasorelaxation  has  been  demonstrated  in  obesity,  type  2 
diabetes, hypertension and dyslipidaemia (Pinkney et al., 1997; Reaven, 1988). 
In  a  small  subgroup  of  patients  obese  normoinsulinaemic  and  hyperinsuliaemic 
patients both had raised circulating ADMA (figure 3.13). The raised ADMA, used as 
an  index  of  endothelial  dysfunction,  was  associated  with  insulin  resistance  in  the   92 
obese hyperinsulinaemic patients but not in the obese normoinsulinaemic group. The 
reason the later “fat and fit” group do not develop insulin resistance is not entirely 
understood. McLaughlin et al. found serum ADMA to be higher in insulin resistant 
obese women compared to their equally obese but insulin sensitive counterparts. They 
reported  serum  ADMA  decreased  after  weight  loss  only  in  the  former  group 
(McLaughlin  et  al.,  2006).  The  same  group  had  treated  healthy  insulin  resistant 
individuals  with  Rosiglitazone,  an  insulin-sensitizing  drug,  and  showed  enhanced 
insulin sensitivity and reduced plasma ADMA concentrations (Stuhlinger et al., 2002), 
concluding that insulin resistance is a potential mediator of ADMA concentrations. 
However  work  by  Naderali  et  al.  showed  severely  reduced  insulin-induced 
vasorelaxation  in  diet  induced  fed  rat  but  concentration-dependent  relaxation  by 
insulin (Naderali et al., 2001) suggesting that endothelial dysfunction comes prior to 
insulin resistance. A randomized placebo controlled study on 70 non-diabetic patients 
with  metabolic  syndrome  demonstrated  an  independent  association  between 
improvement  in  flow-mediated  dilation  and  reductions  in  ADMA  in  patients  on 
Rosiglitazone (Wang et al., 2006).  In our study  the obese normoinsulinaemic and 
hyperinsulinaemic patients on Metformin had lower circulating ADMA compared to 
their  counterparts  not  on  Metformin.  Metformin  has  been  reported  to  decrease 
circulating ADMA both as monotherapy and as add on therapy to sulphonylurea in 
poorly controlled type 2 diabetic patients (Asagami et al., 2002). The modes of action 
of insulin sensitizing drugs are not well understood. Metformin may directly act on 
adipose tissue and enhance adiponectin release, which then inhibits ADMA release 
from the liver or it may have separate effects on adipose tissue and liver (figure 4.1). 
Other studies looked at endothelial vasodilatory function and had reported an inverse 
relationship between ADMA and endothelial function in the hypertensive (Perticone 
et al., 2005) and hypercholestrolaemic patients (Boger et al., 1998). Weight loss has 
also  shown  to  improve  endothelial-dependent  vasodilation  in  obese  individuals 
(Sasaki et al., 2002; Ziccardi et al., 2002). Interestingly adiponectin has been shown 
to reduce ADMA accumulation in human cultured endothelial cells (Eid et al., 2007). 
Serum  adiponectin,  an  insulin  sensitizing  adipokine,  was  lower  in  the  obese 
hyperinsulinaemic  group  compared  to  obese  normoinsulinaemic  individuals  and 
circulating levels seemed to be higher in both groups when on Metformin. Plasma 
adiponectin  have  been  reported  to  be  higher  after  Metformin  treatment  in  obese 
patients with polycyctic ovary syndrome (Jakubowska et al., 2008). Adiponectin acts   93 
through  two  receptors,  AdipoR1  and  AdipoR2.  It  is  thought  that  a  decreased 
expression of these receptors could contribute to insulin resistance and diabetes. A 
study on Zucker diabetic rat found that Metformin induced the expression of these 
receptors in liver muscle and adipose tissue (Metais et al., 2008).  
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Figure 4.1: Proposal of the mechanism of action of Metformin. 
Metformin may act by a) inducing adiponectin secretion from adipose tissue which 
then  has  inhibitory  effect  on  ADMA  release  from  the  liver  and  on  adiponectin 
receptors. b) having direct inhibitory effect on liver ADMA synthesis and release. AT: 
Adipose Tissue 
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The  debate  on  whether  insulin  resistance  is  the  result  or  the  cause  of  endothelial 
dysfunction is not clear. Future longitudinal studies and myography of vessels from 
the adipose tissue may provide a clearer explanation for this. Given the pivotal role of 
ADMA in determining NO bioavailability and the large array of conditions associated 
with high ADMA concentrations, pharmacological modulation of circulating ADMA 
could lead to novel therapies for preventing cardiovascular disease in insulin resistant 
or high risk subjects. If endothelial dysfunction occurs prior to insulin resistance, and 
elevations in serum ADMA represent a reversible abnormality that contributes to the 
increased cardiovascular risk, ADMA modulation may be beneficial in  preventing 
obesity associated cardiovascular dysfunction in insulin sensitive individuals.  
 
4.4  LIMITATIONS OF RECRUITMENT 
Two main limitations of this study were encountered during recruitment phase. While 
setting up the protocol it was decided that obese patients would be recruited from the 
patient group undergoing bariatric surgery and the lean patients would be a group 
undergoing reflux surgery. It was anticipated that 15 obese and 15 lean individuals 
would  be  enrolled  by  the  end  of  the  recruitment  period  for  this  study.  However 
majority of the patients in the later group had BMI>28 (kgm
-2) and therefore were 
considered obese. Out of the total of 31 patients recruited only 4 were lean by WHO 
criteria. This meant that there were not enough lean patients to be used as the control 
group for this study. In order to address this short fall, ethical approval was obtained 
to  include  patients  undergoing  laparoscopic  cholecystectomy.  However  after 
recruitment for few months it was evident that this group of patients were also mainly 
obese.  
The second limitation to this study became evident midway during the recruitment 
period. This was the predominance of female, obese patients. Of the total 31 patients 
recruited, only 6 were male, of whom only 2 were obese. This meant that male obese 
individuals were not represented appropriately and therefore they had to be omitted 
from the study to avoid sex bias. The same applied to Afro-Caribbean individuals, 
who were excluded from all analysis.   
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4.5  LIMITATIONS IN ACQUIRING SAMPLES 
Gastric fat pad biopsies were, at times, technically difficult or the sample not large 
enough. In patients undergoing laparoscopic cholecystectomy the field of operation 
was away from the gastric fat pad and therefore biopsies were not safe.  
 
4.6  CONCLUSIONS 
It is well proven that there are differences in the production/release of adipokines 
between the subcutaneous and visceral depots and visceral adiposity is directly linked 
to cardiovascular risk factors. However in this study we showed that there is also a 
difference  in  the  release  of  at  least  one  adipokine  (RANTES)  between  different 
visceral depots which may suggest paracrine local factors mediating their release.  
IL-6 and ADMA, an endogenous nitric oxide inhibitor, might also explain the link 
between obesity, type 2 diabetes mellitus and cardiovascular disease. PGI2S seems to 
be more coupled to IL-6 production in omental adipose tissue and ADMA release was 
higher  from  the  omental  depot.  Modulation  of  these  adipokines  may  reduce  the 
cardiovascular risks associated with obesity.   
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